US20110015205A1 - Trazodone Composition for Once a Day Administration - Google Patents
Trazodone Composition for Once a Day Administration Download PDFInfo
- Publication number
- US20110015205A1 US20110015205A1 US12/892,466 US89246610A US2011015205A1 US 20110015205 A1 US20110015205 A1 US 20110015205A1 US 89246610 A US89246610 A US 89246610A US 2011015205 A1 US2011015205 A1 US 2011015205A1
- Authority
- US
- United States
- Prior art keywords
- trazodone
- sustained release
- pharmaceutical composition
- composition according
- release pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- PHLBKPHSAVXXEF-UHFFFAOYSA-N Cl.O=C1N(CCCN2CCN(C3=CC=CC(Cl)=C3)CC2)N=C2C=CC=CN12 Chemical compound Cl.O=C1N(CCCN2CCN(C3=CC=CC(Cl)=C3)CC2)N=C2C=CC=CN12 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Definitions
- the present invention relates to the anti-depressant trazodone and in particular to a once a day formulation of trazodone, and to its use for treating depression and certain sleep disorders.
- Trazodone is a serotonin-2 receptor antagonist/reuptake inhibitor that also decreases extracellular gamma-amino-butyric acid (GABA) levels in the cerebral cortex, through the blockade of 5-hydroxytryptamine 2A (5-HT 2A ) receptors. This decrease is accompanied by an increase in (5-HT) release. Higher doses of trazodone inhibit 5-HT transport and this uptake inhibition results in a further increase in 5-HT levels. It is contemplated that this double mechanism may be responsible for the anti-depressant properties of trazodone. Moreover, the interaction between the GABAergic and serotoninergic systems may explain its sedative, anxiolytic properties.
- GABA gamma-amino-butyric acid
- Trazodone is therefore a psychoactive compound with sedative and anti-depressant properties. It is rapidly absorbed from the upper gastro-intestinal tract and is extensively metabolized after oral administration. It is normally used to relieve symptoms of depression such as feelings of sadness, worthlessness, or guilt; loss of interest in daily activities; changes in appetite; tiredness; thoughts of death or suicide; and insomnia. Trazodone may also be used for other purposes, and details thereof are well documented in the art.
- Trazodone is a triazolopyridine derivative of the formula
- trazodone The solubility of trazodone is pH dependent and has a pKa of 6.74 in water.
- trazodone is highly soluble in acid media (as found in the stomach and upper intestines) i.e., when below its pKa.
- solubility when above its pKa, its solubility is very low, for example, in the neutral and basic conditions of the lower intestine.
- Such insolubility obviously has an effect on its dissolution and, therefore, on the availability of the drug for absorption in the lower intestine.
- trazodone is normally prescribed as an immediate release form for use two times (BID) or three times (TID) a day, with all the inconveniences and disadvantages that this involves.
- BID or TID dosing with immediate release forms of trazodone results in concentrations of the drug in the blood that do not remain within the so-called therapeutic window and which, therefore, can be associated with higher risks of dose related adverse effects when reaching high levels, or lower degree of efficacy when reaching low levels.
- multiple daily doses may lead to several periods of drowsiness throughout the day associated with peak trazodone concentrations occurring immediately after administration.
- the invention provides a sustained release pharmaceutical composition for once a day oral administration or trazodone or a derivative thereof.
- the composition comprises from about 15% to about 60% by weight trazodone or a derivative thereof, and from about 15% to about 85% by weight percent of a controlled release excipient.
- the controlled release excipient when orally administered to a mammal, for example, a person, permits the trazodone or derivative thereof to achieve an effective plasma concentration from at least about 1 hour to about 24 hours after initial administration. Under certain circumstances, the controlled release excipient provides a substantially pH independent controlled release of the trazodone or derivative thereof so that the trazodone or the trazodone derivative can be absorbed during passage through both the upper and lower gastrointestinal tracts.
- the sustained release formulations provide plasma concentrations of trazodone or trazodone derivatives for at least 24 hours that are effective at treating, i.e., ameliorating, one or more of the symptoms of depression.
- the sustained release formulations provide effective amounts of trazodone or a trazodone derivative for treating sleeping disorders, for example, improving sleep architecture.
- the sustained release excipient can provide a therapeutically effective plasma trazodone or trazodone derivative concentration that remains substantially constant between about 50 ng/mL and about 3000 ng/mL for a period that extends about one hour after ingestion to at least about 24 hours. Plasma concentrations typically are dependent on the dose administered.
- a sustained release pharmaceutical composition contemplated herein comprises 150 mg of trazodone hydrochloride. Such a formulation provides an effective plasma trazodone concentration from at least about 1 hour to about 24 hours after initial administration of between about 150 ng/mL and about 500 ng/mL.
- the sustained release pharmaceutical composition comprises 300 mg of trazodone hydrochloride. Such a formulation provides an effective plasma trazodone concentration from at least about 1 hour to about 24 hours after initial administration of between about 300 ng/mL and about 1000 ng/mL.
- the sustained release pharmaceutical composition comprises from about 15% to about 60% by weight trazodone or a derivative thereof and from about 15% to about 85% by weight percent of controlled release excipient. In other embodiments, the composition comprises from about 20% to about 50% weight percent trazodone and from about 20% to about 50% weight percent of controlled release excipient. For example, the composition may comprise about 35% to about 50% weight percent trazodone and from about 15% to about 50% weight percent of controlled release excipient.
- the controlled release excipient comprises cross-linked high amylose starch.
- the cross-linked high amylose starch is cross linked with phosphorus oxychloride and/or comprises hydroxypropyl side chains.
- the cross-linked high amylose starch comprises between about 65% and 75% by weight amylose and is cross-linked with phosphorus oxychloride.
- CONTRAMID® cross-linked, high amylose starch available commercially from Labopharm, Inc., Laval, Canada.
- the sustained release pharmaceutical composition may optionally include more or more pharmaceutical additives.
- exemplary pharmaceutical additives include binding agents (for example, hydroxypropylmethylcellulose), solubilizing agents (for example, povidone or cetylpyridinium chloride), acidifying agents (for example, alginic acid), pore forming agents (for example, sucrose), lubricants (for example, sodium stearyl fumarate), and glidants (for example, colloidal silicon dioxide).
- the invention provides a sustained release pharmaceutical composition
- a sustained release pharmaceutical composition comprising about 20% to about 50% by weight trazodone hydrochloride, about 20% to about 50% by weight cross-linked high amylose starch, about 10% to about 20% by weight hydroxypropylmethylcellulose, about 0% to about 5% by weight cetylpyridinium chloride, about 0% to about 20% by weight alginic acid, about 1% to about 5% by weight percent sodium stearyl fumarate, and up to about 1% by weight percent colloidal silicon dioxide.
- the sustained release pharmaceutical composition can be formulated into a variety of shapes and forms such as tablets and caplets suitable for oral administration.
- the invention provides a caplet comprising 300 mg of trazodone.
- a caplet can be adapted for administration before bedtime.
- Such a formulation rapidly induces somnolence after oral administration but yet provides substantially no drowsiness in a patient about 8 hours after oral administration as compared to repeat administration of an immediate release trazodone composition.
- the invention provides for unit dose sustained release pharmaceutical composition for once a day oral administration of 300 mg trazodone hydrochloride is comprising about 20% to about 40% by weight of a controlled release excipient, wherein when ingested orally, the composition provides area under the concentration-time curve substantially equivalent to the commercially available daily dose of three 100 mg strength trazodone hydrochloride tablets, wherein the three tablets are administered over 24 hours.
- a unit dose sustained release pharmaceutical composition for once a day oral administration of 150 mg trazodone hydrochloride comprising about 30% to about 50% by weight of a controlled release excipient, wherein when ingested orally, the composition provides area under the concentration-time curve substantially equivalent to the commercially available daily dose of three, 50 mg strength trazodone hydrochloride tablets, wherein the three tablets are administered over 24 hours.
- the invention provides a method of treating depression by administering once a day to a person in need of an anti-depressant, one of the sustained release pharmaceutical compositions described above.
- the composition can be administered before bedtime.
- the invention provides a method of improving the sleep architecture in a person in need of treatment thereof, the method comprises administering once a day to such a person, one of the sustained release pharmaceutical compositions described above.
- the composition preferably is administered before bedtime.
- FIG. 1 is a graph illustrating the in vitro dissolution profile of a first 300 mg trazodone OAD formulation
- FIG. 2 is graph that illustrates the plasma trazodone concentration derived from a single tablet of the first 300 mg trazodone OAD formulation as a function of time when administered to a human;
- FIG. 3 is a graph illustrating the in vitro dissolution profile of a second 300 mg trazodone OAD formulation
- FIG. 4 is graph that illustrates the plasma trazodone concentration derived from a single tablet of a second 300 mg trazodone OAD formulation as a function of time when administered to a human;
- FIG. 5 is a graph illustrating the in vitro dissolution profile of a 150 mg trazodone OAD formulation.
- FIG. 6 is graph that illustrates the plasma trazodone concentration derived from a single tablet of a 150 mg trazodone OAD formulation as a function of time when administered to a human.
- the invention is based, in part, upon the discovery that it is possible to formulate a once a day formulation of trazodone or a trazodone derivative that provides a plasma concentration of the active ingredient that is essentially stable between one hour and twenty four hours that is effective in the treatment of, i.e., ameliorating one or more of the systems of depression.
- This discovery was surprising because, even though the solubility of trazodone is pH dependent, and decreases rapidly at the higher pH found in the lower gastrointestinal tract, it has been found that it is possible to provide therapeutic, stable and/or effective concentrations of trazodone in the blood stream for at least 24 hours irrespective of changes in pH through the upper and lower intestinal tracts.
- the invention provides a sustained release pharmaceutical composition for once a day oral administration or trazodone or a derivative thereof.
- the composition comprises from about 15% to about 60% by weight trazodone or a derivative thereof, and from about 15% to about 85% by weight percent of a controlled release excipient.
- the controlled release excipient when orally administered to a mammal, for example, a person, permits the trazodone or derivative thereof to achieve and/or maintain an effective plasma concentration, for example, a therapeutically effective plasma concentration from at least about 1 hour to about 24 hours after initial administration for treating depression.
- the same or similar formulations for treating sleep disorders, for example, improving sleep architecture.
- the controlled release excipient when orally administered to a mammal, for example, a person, permits the trazodone or derivative thereof to achieve an effective plasma concentration for treating a sleep disorder.
- Such a formulation rapidly (for example, within 1 hour) induces somnolence after oral administration but yet provides substantially no drowsiness in a patient about 8 hours after oral administration, as compared to repeat administration of an immediate release trazodone composition.
- the formulations described herein provide a rapid rise in plasma concentrations of the active ingredient, which thereafter remain relatively and substantially stable for at least 24 hours or more.
- the plasma concentration between 1 hour and 24 hours remains within about 45% of the mean plasma concentration, more preferably between about 30% of the mean plasma concentration, and most preferably between about 15% of the mean plasma concentration.
- the trazodone or the trazodone derivative is released in vivo with approximately zero order kinetics for at least about 24 hours, leading to plateau plasma concentrations.
- the effective plasma concentration of the trazodone formulation remains generally constant about 1 hour after ingestion, and can be between about 60 ng/mL and about 3000 ng/mL, between about 150 ng/mL and 1500 ng/mL, between about 600 ng/mL and 1300 ng/mL, between about 500 ng/mL and 1200 ng/mL, or between about 300 ng/mL and 650 ng/mL at least up to about 24 hours after oral administration.
- Formulations contemplated herein may reach steady-state, for example, on-average, within a normal population, after about the fourth administration.
- the peak-to-trough ratio produced by such formulations at steady-state may be about 60% to about 100%.
- the sustained release trazodone formulations contemplated herein may have effective plasma concentrations that are for example bioequivalent with respect to the AUC (area under the curve) of a immediate release formulation that is administered, for example, two or three times day.
- the AUC is a mathematical calculation to evaluate the body's total exposure over time to a given drug and refers to the area under the curve in a plot of concentration of drug against time. AUC's are used as a guide for dosing schedules and to compare the bioavailability of different drug formulations in the body.
- formulations described herein are particularly useful in the delivery of trazodone and trazodone derivatives.
- Derivatives include pharmaceutically acceptable prodrugs, metabolites, salts and esters, or the like of trazodone.
- pharmaceutically-acceptable salts is art-recognized and refers to the relatively non-toxic, inorganic and organic acid addition salts of compounds, including, for example, those contained in compositions of the present invention.
- the active ingredient in the formulation is trazodone hydrochloride.
- compositions according to the invention may include trazodone or its derivatives and a controlled release excipient.
- compositions disclosed herein include more than about 15% trazodone or its derivatives by weight, for example between about 15% and about 60%, or between about 20% and about 60%, or between about 20% and about 55% by weight.
- compositions contemplated herein may include more than about 15% weight controlled release excipient, for example, between about, 15% and about 85%, or about 20% and about 85%, or about 20% and about 60%, or about 20% and about 50%, or about 30% to about 50% by weight.
- composition according to the invention preferably comprises from about 20% to about 50% by weight, more preferably from about 25% to about 50% trazodone or trazodone derivative, and from about 20% to 50% by weight, more preferably from about 25% to about 50% by weight of controlled release excipient.
- this invention is directed to a composition comprising about 25% to about 50% trazodone hydrochloride by weight and about 30% to about 50% cross-linked high amylose starch, such as disclosed herein.
- a practical example of a sustained release pharmaceutical composition according to the invention is one containing 150 mg of trazodone hydrochloride.
- This formulation can provide an effective plasma concentration preferably in the range of about 150 ng/mL to 500 ng/mL between about 1 and 24 hours after the first administration.
- Another practical example is one wherein the composition comprises 300 mg of trazodone hydrochloride.
- This formulation can provide a plasma trazodone concentration preferably in the range of about 300 ng/mL to 1000 ng/mL.
- other compositions according to the invention may be prepared with different amounts of trazodone or its derivatives with correspondingly varying plasma concentrations that can be for example, between about 50 ng/mL and about 3000 ng/mL.
- Controlled release excipients contemplated herein may vary to a large extent as is well known to one skilled in the art, provided that a formulation including an excipient has the disclosed therapeutic action and/or provides a pH independent delivery of trazodone or a trazodone derivative.
- Controlled release excipients may include cross-linked starches, hydrogels, celluloses, and/or polymers, and other controlled release excipients known to those skilled in the art.
- the controlled release excipient preferably comprises a cross-linked high amylose starch, for example, where the cross-linked high amylose starch is cross-linked with phosphorus oxychloride and/or comprises hydroxypropyl side chains.
- the cross-linked high amylose starch comprises between about 65% and 75% by weight amylose and is cross-linked with phosphorus oxychloride.
- a suitable excipient has been developed by and is available commercially from Labopharm, Inc., Laval, Canada, under the trademark CONTRAMID®. The synthesis of the CONTRAMID® excipient is described, for example, in U.S. Pat. No. 6,607,748, hereby incorporated by reference in its entirety for all purposes.
- Compositions contemplated herein may include cross-linked high amylose starch together with one or more additional controlled release excipients.
- Cross-linking of starch represents a powerful method for modifying starch.
- starch granules are cross-linked to increase resistance of the paste to shear or heat.
- Such chemically cross-linked starches provide a desirable smooth texture and possess viscosity stability throughout processing operations and normal shelf life.
- cross-linked high amylose starch as contemplated herein may be gelatinized after cross-linking.
- cross-linking high amylose starch may include additional chemical modification (e.g., hydroxypropylation) prior to gelatinization.
- cross-linking of high amylose starch may be realized according to procedures described in the art.
- cross-linking of amylose can be carried out in the manner described in Mateescu [B IOCHEMIE 60: 535-537 (1978)] by reacting amylose with epichlorohydrin in an alkaline medium.
- starch can also be cross-linked with a reagent selected from the group consisting of epichlorohydrin, adipic acid anhydride, sodium trimetaphosphate and phosphorous oxychloride or other cross-linking agents including, but not limited to, 2,3-dibromopropanol, linear mixed anhydrides of acetic and di- or tribasic carboxylic acids, vinyl sulfone, diepoxides, cyanuric chloride, hexahydro-1,3,5-trisacryloyl-s-triazine, hexamethylene diisocyanate, toluene 2,4-diisocyanate, N,N-methylenebisacrylamide, N,N′-bis (hydroxymethyl) ethyleneurea, mixed carbonic-carboxylic acid anhydrides, imidazolides of carbonic and polybasic carboxylic acids, imidazolium salts of polybasic carboxylic acids, and guanidine derivatives
- starches containing more than about 40% w/w amylose can be used to form cross-linked high amylose starch, e.g., pea and wrinkled pea starch, bean starch, hybrids or genetically modified tapioca or potato starch, or any other root, tuber or cereal starch.
- high amylose starch containing about 70% w/w amylose is used as the base material.
- high amylose starch, Cerestar AmyloGel 03003 Cerestar U.S.A. Inc.
- trazodone or a trazodone derivative with a controlled release excipient, for example, cross-linked high amylase starch (for example, CONTRAMID® cross-linked high amylose starch), trazodone, which is pH sensitive with a pKa of about 6.74 can be released and absorbed not only in the upper gastrointestinal tract where the pH is below the pKa of trazodone (where trazodone is soluble) but also in the lower gastrointestinal tract where the pH is above the pKa of trazodone (where trazodone is poorly soluble) thereby maintaining stable plasma concentrations in the blood throughout gastrointestinal transit.
- a controlled release excipient for example, cross-linked high amylase starch (for example, CONTRAMID® cross-linked high amylose starch)
- trazodone which is pH sensitive with a pKa of about 6.74 can be released and absorbed not only in the upper gastrointestinal tract where the pH is below
- the pharmaceutical composition according to the invention may also comprise pharmaceutically acceptable additives.
- additives can include, for example, sugars, such as lactose, glucose and sucrose; other starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; and other non-toxic compatible substances employed in pharmaceutical formulations.
- additives may also include colorants.
- compositions disclosed herein may include any one of a mixture of a binding agent, a solubilizing agent, an acidifying agent, a pore forming agent, a lubricant, a glidant, and the like, as is well known to those skilled in the art.
- Preferred pharmaceutical additives that are used in providing a composition according to the invention may include, for example, binding agents that include, for example, hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, dicalcium phosphate, calcium phosphate, microcrystalline cellulose, or the like, solubilizing agents that include, for example, povidone, cetylpyridinium chloride, or the like, acidifying agents that include, for example, alginic acid, citric acid, succinic acid, bile acid or the like, pore forming agents, that include, for example, sucrose, lactose, mannitol or the like, lubricants that include, for example, sodium stearyl fumarate, magnesium stearate, calcium stearate, stearic acid, hydrogentated vegetable oils or the like and/or glidants that include, for example, colloidal silicon dioxide, talc or the like.
- binding agents that include, for example, hydroxypropyl
- the composition according to the invention may comprise about 20 to 50 weight percent trazodone hydrochloride, about 20 to 50 weight percent cross-linked high amylase starch (for example, CONTRAMID® cross-linked high amylose starch), about 10 to 25 weight percent hydroxypropylmethylcellulose, about 0 to 10 weight percent cetylpyridinium chloride, about 0 to 20 weight percent alginic acid, about 1 to 5 weight percent sodium stearyl fumarate, and up to about 1 weight percent colloidal silicon dioxide.
- cross-linked high amylase starch for example, CONTRAMID® cross-linked high amylose starch
- composition according to the invention is normally prepared in the form of a tablet.
- the tablet can adopt a wide variety of shapes as is well known to those skilled in the art, the preferred shape is a caplet.
- Such caplets may be formed using, for example, upper and lower punches as is known in the art.
- tablets may include a coat, such as, for example, a coating with a colorant.
- Suitable coatings include, for example, aqueous film coating polymers such as polyvinyl alcohol, talc, macrogol and the like, and mixtures thereof.
- Suitable colorants include, for example, iron oxides, lakes, natural colorants and other colorants known to those skilled in the art.
- CONTRAMID® excipient hydroxypropylmethyl cellulose, trazodone HCl and sodium stearyl fumarate are individually weighed and sifted through a 30 mesh filter.
- Colloidal silicon dioxide is weighed and pre-blended with CONTRAMID®, sifted through a 30 mesh filter, and blended for 10-30 seconds, for example, 15 seconds to produce a pre-blend.
- Hydroxypropylmethylcellulose, trazodone and the Contramid®-collodial silicon dioxide pre-blend are combined and blended for 5-10 minutes, for example, 7 minutes, to produce a bulk blend.
- a small portion of the resulting bulk blend is combined with the sodium stearyl fumarate and blended for 20-60 seconds, for example, 30 seconds.
- the resulting sodium stearyl fumarate blend is combined with the residual bulk blend, and the resulting mixture blended for about 2-6 minutes, for example, 4 minutes.
- the final blend is compressed into tablets using a compression pressure of 27 kN. Caplets are formed using a caplet standard concave punch.
- a dosage for once a day administration may be 25 mg to 600 mg of trazodone or a trazodone derivative.
- Typical doses for once a day administration include 150 mg or 300 mg of trazodone or a trazodone derivative, although this amount may vary to a large extent depending on required needs, and the specific requirements of the treating physician.
- the dosage of any compositions of the present invention will vary depending on the symptoms, age and body weight of the patient, the nature and severity of the disorder to be treated or prevented, the route of administration, and the form of the subject composition. Dosages for the compositions of the present invention may be readily determined by techniques known to those of skill in the art or as taught herein.
- the precise time of administration and amount of any particular subject composition that will yield the most effective treatment in a given patient will depend upon the activity, pharmacokinetics, and bioavailability of a subject composition, physiological condition of the patient (including age, sex, disease type and stage, general physical condition, responsiveness to a given dosage and type of medication), route of administration, and the like.
- the guidelines presented herein may be used to optimize the treatment, e.g., determining the optimum time and/or amount of administration, which will require no more than routine experimentation consisting of monitoring the subject and adjusting the dosage and/or timing.
- the resulting formulations have in vitro profiles, preferably, as described in Examples 1 and 3, hereinbelow.
- the in vitro release profiles were measured as follows. Briefly, the release rates were determined using a U.S.P. paddle method (apparatus type II as described in U.S.P. XXVI) at 150 revolutions per minute, at 37 ⁇ 0.5° C., in 900 mL of hydrochloride/sodium chloride pH 1.2 solution (acid stage) followed after one hour by 900 mL of sodium phosphate monobasic buffer pH 6.0 (buffer stage).
- formulations may have release kinetics, whereby, when tested by the foregoing method, not more than about 30% of the active ingredient is released by 1 hour after initiation of the experiment, about 35% to 60% of the active ingredient is released by 6 hours, not more than about 80% of the active ingredient is released by 12 hours, and/or not less than about 80% of the active ingredient is released by 24 hours.
- compositions described herein are particularly useful in treating depression, disorders associated with depression, and sleep disorders.
- a mammal suffering from depression can be administered once a day (for example, at bedtime) with a trazodone formulation as defined above.
- a mammal to be treated by the subject method may mean either a human or non-human animal.
- compositions described herein may also be useful in treating patients that have difficulty sleeping and/or have disrupted sleep architecture, i.e., disrupted non-REM/REM stage and cycle infrastructure of sleep.
- formulations disclosed herein release a therapeutically effective portion of trazodone within one hour after oral administration and thus rapidly induce somnolence but yet provide substantially no drowsiness in a patient about 8 hours after oral administration as compared to repeat administration of an immediate release trazodone composition. Accordingly, such formulations reduce undesirable drowsiness in waking hours or in the day time.
- a first sustained release 300 mg trazodone containing formulation (denoted Formulation 1) was prepared having the composition set forth in TABLE 1.
- This formulation when tested using the foregoing method, had an in vitro release profile where not more than about 30% of the active ingredient was released by 1 hour after initiation of the experiment, about 35% to 55% of the active ingredient was released by 6 hours, not more than 80% of the active ingredient was released by 12 hours, and not less than 80% of the active ingredient was released by 24 hours.
- the formulation was tested in vivo.
- the pharmacokinetics of this formulation were compared with those of the commercial products Trittico® AC 150 mg CR tablets given BID, and Desyrel® 100 mg IR tablets given TID in a human randomized pharmacokinetic crossover study. It was found that following administration of Formulation 1, trazodone plasma concentrations increased more gradually and peak trazodone plasma concentrations were lower than those of either of the reference products.
- the mean plasma trazodone concentration measured in 18 patients is shown in FIG. 2 .
- the results indicate that this formulation provides a therapeutic plasma concentration within about 1 hour and provides a substantially constant trazodone concentration from 1 hour to 24 hours.
- the trazodone plasma concentrations at 24 hours were similar to those following TID administration of Desyrel® and BID administration of Trittico® AC.
- a second sustained release 300 mg trazodone containing formulation (denoted Formulation 2) was prepared having the composition set forth in TABLE 2.
- the in vitro release kinetics of Formulation 2 were measured using the U.S.P. paddle method as described in Example 1.
- the in vitro dissolution profile ( FIG. 3 ) shows that in this formulation, not more than about 30% of the active ingredient was released by 1 hour after initiation of the experiment, about 35% to 55% of the active ingredient was released by 6 hours, not more than 80% of the active ingredient was released by 12 hours, and not less than 80% of the active ingredient was released by 24 hours
- Formulation 2 was also evaluated in vivo. The results obtained were substantially the same when Formulation 2 was compared with Trittico® AC and Desyrel®. The mean plasma trazodone concentration measured in 19 patients is shown in FIG. 4 . It was found that following administration of Formulation 2, trazodone plasma concentrations increased to provide a therapeutic concentration in about 1 hour. The plasma concentrations increased till about 6 hours after oral administration but then gradually declined. The plasma concentration of trazodone provided by Formulation 1 was more stable between 1 hours and 24 hours than that provided by Formulation 2.
- a first sustained release 150 mg trazodone containing formulation (denoted Formulation 3) was prepared having the composition set forth in TABLE 3.
- the in vitro release kinetics of Formulation 3 were measured using the U.S.P. paddle method as described in Example 1.
- the in vitro dissolution profile ( FIG. 5 ) shows that in this formulation, not more than about 30% of the active ingredient was released by 1 hour after initiation of the experiment, about 40% to 60% of the active ingredient was released by 6 hours, not more than 80% of the active ingredient was released by 12 hours, and not less than 80% of the active ingredient was released by 24 hours.
- Formulation 2 was also evaluated in vivo.
- the mean plasma trazodone concentration measured in 18 patients is shown in FIG. 6 . It was found that following administration of Formulation 3, trazodone plasma concentrations increased rapidly to provide a therapeutic concentration in about 1 hour. The results indicate a substantially constant trazodone concentration from 1 hour to 24 hours. As with formulation 1, this appears to show zero order release kinetics between 1 hour and 24 hours following oral administration.
Abstract
Description
- This application claims the benefit of U.S. Provisional Patent Application Ser. No. 60/715,162, filed Sep. 9, 2005, the entire disclosure of which is incorporated by reference herein.
- The present invention relates to the anti-depressant trazodone and in particular to a once a day formulation of trazodone, and to its use for treating depression and certain sleep disorders.
- Trazodone is a serotonin-2 receptor antagonist/reuptake inhibitor that also decreases extracellular gamma-amino-butyric acid (GABA) levels in the cerebral cortex, through the blockade of 5-hydroxytryptamine2A (5-HT2A) receptors. This decrease is accompanied by an increase in (5-HT) release. Higher doses of trazodone inhibit 5-HT transport and this uptake inhibition results in a further increase in 5-HT levels. It is contemplated that this double mechanism may be responsible for the anti-depressant properties of trazodone. Moreover, the interaction between the GABAergic and serotoninergic systems may explain its sedative, anxiolytic properties.
- Trazodone is therefore a psychoactive compound with sedative and anti-depressant properties. It is rapidly absorbed from the upper gastro-intestinal tract and is extensively metabolized after oral administration. It is normally used to relieve symptoms of depression such as feelings of sadness, worthlessness, or guilt; loss of interest in daily activities; changes in appetite; tiredness; thoughts of death or suicide; and insomnia. Trazodone may also be used for other purposes, and details thereof are well documented in the art.
- Trazodone is a triazolopyridine derivative of the formula
- which is shown in its normally used hydrochloride form. Preparation of this compound was first disclosed in U.S. Pat. No. 3,381,009 which issued in 1968 to G. Palazzo et al.
- The solubility of trazodone is pH dependent and has a pKa of 6.74 in water. As a result, trazodone is highly soluble in acid media (as found in the stomach and upper intestines) i.e., when below its pKa. In contrast, when above its pKa, its solubility is very low, for example, in the neutral and basic conditions of the lower intestine. Such insolubility obviously has an effect on its dissolution and, therefore, on the availability of the drug for absorption in the lower intestine. These features would be expected to hinder the development of long acting (for example, greater than 8 hours) forms of trazodone, which require substantially uniform absorption along the length of the gastrointestinal tract, in particular, absorption during passage through both the upper and lower intestinal tracts.
- As with many drugs, trazodone is normally prescribed as an immediate release form for use two times (BID) or three times (TID) a day, with all the inconveniences and disadvantages that this involves. For example, BID or TID dosing with immediate release forms of trazodone results in concentrations of the drug in the blood that do not remain within the so-called therapeutic window and which, therefore, can be associated with higher risks of dose related adverse effects when reaching high levels, or lower degree of efficacy when reaching low levels. In addition, multiple daily doses may lead to several periods of drowsiness throughout the day associated with peak trazodone concentrations occurring immediately after administration.
- As a result, there is a need for a once a day (OAD) formulation of trazodone that from a single tablet rapidly achieves and maintains stable, effective concentrations over 24 hours and more and that is pH-independent in its release profile so that trazodone may be uniformly absorbed along substantially the entirety of the upper and lower gastrointestinal tract, thereby reducing the frequency and severity of side effects such as drowsiness during the day.
- The invention provides a sustained release pharmaceutical composition for once a day oral administration or trazodone or a derivative thereof. The composition comprises from about 15% to about 60% by weight trazodone or a derivative thereof, and from about 15% to about 85% by weight percent of a controlled release excipient. The controlled release excipient, when orally administered to a mammal, for example, a person, permits the trazodone or derivative thereof to achieve an effective plasma concentration from at least about 1 hour to about 24 hours after initial administration. Under certain circumstances, the controlled release excipient provides a substantially pH independent controlled release of the trazodone or derivative thereof so that the trazodone or the trazodone derivative can be absorbed during passage through both the upper and lower gastrointestinal tracts.
- The sustained release formulations provide plasma concentrations of trazodone or trazodone derivatives for at least 24 hours that are effective at treating, i.e., ameliorating, one or more of the symptoms of depression. In another embodiment, the sustained release formulations provide effective amounts of trazodone or a trazodone derivative for treating sleeping disorders, for example, improving sleep architecture.
- The sustained release excipient can provide a therapeutically effective plasma trazodone or trazodone derivative concentration that remains substantially constant between about 50 ng/mL and about 3000 ng/mL for a period that extends about one hour after ingestion to at least about 24 hours. Plasma concentrations typically are dependent on the dose administered. For example, in one embodiment, a sustained release pharmaceutical composition contemplated herein comprises 150 mg of trazodone hydrochloride. Such a formulation provides an effective plasma trazodone concentration from at least about 1 hour to about 24 hours after initial administration of between about 150 ng/mL and about 500 ng/mL. In another embodiment, the sustained release pharmaceutical composition comprises 300 mg of trazodone hydrochloride. Such a formulation provides an effective plasma trazodone concentration from at least about 1 hour to about 24 hours after initial administration of between about 300 ng/mL and about 1000 ng/mL.
- In certain embodiments, the sustained release pharmaceutical composition comprises from about 15% to about 60% by weight trazodone or a derivative thereof and from about 15% to about 85% by weight percent of controlled release excipient. In other embodiments, the composition comprises from about 20% to about 50% weight percent trazodone and from about 20% to about 50% weight percent of controlled release excipient. For example, the composition may comprise about 35% to about 50% weight percent trazodone and from about 15% to about 50% weight percent of controlled release excipient.
- It is contemplated that a number of different excipients may be useful in the practice of the invention. In one embodiment, the controlled release excipient comprises cross-linked high amylose starch. In certain embodiments, the cross-linked high amylose starch is cross linked with phosphorus oxychloride and/or comprises hydroxypropyl side chains. In certain embodiments, the cross-linked high amylose starch comprises between about 65% and 75% by weight amylose and is cross-linked with phosphorus oxychloride. One preferred cross-linked high amylose starch useful in the practice of the invention is known as CONTRAMID® cross-linked, high amylose starch, available commercially from Labopharm, Inc., Laval, Canada.
- In addition, the sustained release pharmaceutical composition may optionally include more or more pharmaceutical additives. Exemplary pharmaceutical additives include binding agents (for example, hydroxypropylmethylcellulose), solubilizing agents (for example, povidone or cetylpyridinium chloride), acidifying agents (for example, alginic acid), pore forming agents (for example, sucrose), lubricants (for example, sodium stearyl fumarate), and glidants (for example, colloidal silicon dioxide).
- In one embodiment, the invention provides a sustained release pharmaceutical composition comprising about 20% to about 50% by weight trazodone hydrochloride, about 20% to about 50% by weight cross-linked high amylose starch, about 10% to about 20% by weight hydroxypropylmethylcellulose, about 0% to about 5% by weight cetylpyridinium chloride, about 0% to about 20% by weight alginic acid, about 1% to about 5% by weight percent sodium stearyl fumarate, and up to about 1% by weight percent colloidal silicon dioxide.
- The sustained release pharmaceutical composition can be formulated into a variety of shapes and forms such as tablets and caplets suitable for oral administration. In one embodiment, the invention provides a caplet comprising 300 mg of trazodone. Such a caplet can be adapted for administration before bedtime. Such a formulation rapidly induces somnolence after oral administration but yet provides substantially no drowsiness in a patient about 8 hours after oral administration as compared to repeat administration of an immediate release trazodone composition.
- The invention provides for unit dose sustained release pharmaceutical composition for once a day oral administration of 300 mg trazodone hydrochloride is comprising about 20% to about 40% by weight of a controlled release excipient, wherein when ingested orally, the composition provides area under the concentration-time curve substantially equivalent to the commercially available daily dose of three 100 mg strength trazodone hydrochloride tablets, wherein the three tablets are administered over 24 hours. Also provided herein is a unit dose sustained release pharmaceutical composition for once a day oral administration of 150 mg trazodone hydrochloride comprising about 30% to about 50% by weight of a controlled release excipient, wherein when ingested orally, the composition provides area under the concentration-time curve substantially equivalent to the commercially available daily dose of three, 50 mg strength trazodone hydrochloride tablets, wherein the three tablets are administered over 24 hours.
- In addition, the invention provides a method of treating depression by administering once a day to a person in need of an anti-depressant, one of the sustained release pharmaceutical compositions described above. The composition can be administered before bedtime.
- In addition, the invention provides a method of improving the sleep architecture in a person in need of treatment thereof, the method comprises administering once a day to such a person, one of the sustained release pharmaceutical compositions described above. The composition preferably is administered before bedtime.
- The invention is illustrated but is not limited by the annexed drawings, in which
-
FIG. 1 is a graph illustrating the in vitro dissolution profile of a first 300 mg trazodone OAD formulation; -
FIG. 2 is graph that illustrates the plasma trazodone concentration derived from a single tablet of the first 300 mg trazodone OAD formulation as a function of time when administered to a human; -
FIG. 3 is a graph illustrating the in vitro dissolution profile of a second 300 mg trazodone OAD formulation; -
FIG. 4 is graph that illustrates the plasma trazodone concentration derived from a single tablet of a second 300 mg trazodone OAD formulation as a function of time when administered to a human; -
FIG. 5 is a graph illustrating the in vitro dissolution profile of a 150 mg trazodone OAD formulation; and -
FIG. 6 is graph that illustrates the plasma trazodone concentration derived from a single tablet of a 150 mg trazodone OAD formulation as a function of time when administered to a human. - The invention is based, in part, upon the discovery that it is possible to formulate a once a day formulation of trazodone or a trazodone derivative that provides a plasma concentration of the active ingredient that is essentially stable between one hour and twenty four hours that is effective in the treatment of, i.e., ameliorating one or more of the systems of depression. This discovery was surprising because, even though the solubility of trazodone is pH dependent, and decreases rapidly at the higher pH found in the lower gastrointestinal tract, it has been found that it is possible to provide therapeutic, stable and/or effective concentrations of trazodone in the blood stream for at least 24 hours irrespective of changes in pH through the upper and lower intestinal tracts.
- Accordingly, the invention provides a sustained release pharmaceutical composition for once a day oral administration or trazodone or a derivative thereof. The composition comprises from about 15% to about 60% by weight trazodone or a derivative thereof, and from about 15% to about 85% by weight percent of a controlled release excipient. The controlled release excipient, when orally administered to a mammal, for example, a person, permits the trazodone or derivative thereof to achieve and/or maintain an effective plasma concentration, for example, a therapeutically effective plasma concentration from at least about 1 hour to about 24 hours after initial administration for treating depression.
- In addition, it is possible to use the same or similar formulations for treating sleep disorders, for example, improving sleep architecture. The controlled release excipient, when orally administered to a mammal, for example, a person, permits the trazodone or derivative thereof to achieve an effective plasma concentration for treating a sleep disorder. Such a formulation rapidly (for example, within 1 hour) induces somnolence after oral administration but yet provides substantially no drowsiness in a patient about 8 hours after oral administration, as compared to repeat administration of an immediate release trazodone composition.
- The formulations described herein provide a rapid rise in plasma concentrations of the active ingredient, which thereafter remain relatively and substantially stable for at least 24 hours or more. The plasma concentration between 1 hour and 24 hours remains within about 45% of the mean plasma concentration, more preferably between about 30% of the mean plasma concentration, and most preferably between about 15% of the mean plasma concentration. In certain formulations, after an initial rapid release of trazodone or the trazodone derivative within an hour of ingestion the trazodone or the trazodone derivative is released in vivo with approximately zero order kinetics for at least about 24 hours, leading to plateau plasma concentrations. In these formulations, the effective plasma concentration of the trazodone formulation remains generally constant about 1 hour after ingestion, and can be between about 60 ng/mL and about 3000 ng/mL, between about 150 ng/mL and 1500 ng/mL, between about 600 ng/mL and 1300 ng/mL, between about 500 ng/mL and 1200 ng/mL, or between about 300 ng/mL and 650 ng/mL at least up to about 24 hours after oral administration.
- Formulations contemplated herein may reach steady-state, for example, on-average, within a normal population, after about the fourth administration. The peak-to-trough ratio produced by such formulations at steady-state may be about 60% to about 100%.
- The sustained release trazodone formulations contemplated herein may have effective plasma concentrations that are for example bioequivalent with respect to the AUC (area under the curve) of a immediate release formulation that is administered, for example, two or three times day. The AUC is a mathematical calculation to evaluate the body's total exposure over time to a given drug and refers to the area under the curve in a plot of concentration of drug against time. AUC's are used as a guide for dosing schedules and to compare the bioavailability of different drug formulations in the body.
- The formulations described herein are particularly useful in the delivery of trazodone and trazodone derivatives. Derivatives include pharmaceutically acceptable prodrugs, metabolites, salts and esters, or the like of trazodone. For example, the term “pharmaceutically-acceptable salts” is art-recognized and refers to the relatively non-toxic, inorganic and organic acid addition salts of compounds, including, for example, those contained in compositions of the present invention. In a preferred embodiment, the active ingredient in the formulation is trazodone hydrochloride.
- A composition according to the invention may include trazodone or its derivatives and a controlled release excipient. In some embodiments, compositions disclosed herein include more than about 15% trazodone or its derivatives by weight, for example between about 15% and about 60%, or between about 20% and about 60%, or between about 20% and about 55% by weight. In other embodiments, compositions contemplated herein may include more than about 15% weight controlled release excipient, for example, between about, 15% and about 85%, or about 20% and about 85%, or about 20% and about 60%, or about 20% and about 50%, or about 30% to about 50% by weight. The composition according to the invention preferably comprises from about 20% to about 50% by weight, more preferably from about 25% to about 50% trazodone or trazodone derivative, and from about 20% to 50% by weight, more preferably from about 25% to about 50% by weight of controlled release excipient. In a particular embodiment, this invention is directed to a composition comprising about 25% to about 50% trazodone hydrochloride by weight and about 30% to about 50% cross-linked high amylose starch, such as disclosed herein.
- A practical example of a sustained release pharmaceutical composition according to the invention, is one containing 150 mg of trazodone hydrochloride. This formulation can provide an effective plasma concentration preferably in the range of about 150 ng/mL to 500 ng/mL between about 1 and 24 hours after the first administration. Another practical example is one wherein the composition comprises 300 mg of trazodone hydrochloride. This formulation can provide a plasma trazodone concentration preferably in the range of about 300 ng/mL to 1000 ng/mL. Of course, other compositions according to the invention may be prepared with different amounts of trazodone or its derivatives with correspondingly varying plasma concentrations that can be for example, between about 50 ng/mL and about 3000 ng/mL.
- Controlled release excipients contemplated herein may vary to a large extent as is well known to one skilled in the art, provided that a formulation including an excipient has the disclosed therapeutic action and/or provides a pH independent delivery of trazodone or a trazodone derivative. Controlled release excipients may include cross-linked starches, hydrogels, celluloses, and/or polymers, and other controlled release excipients known to those skilled in the art.
- In one embodiment, the controlled release excipient preferably comprises a cross-linked high amylose starch, for example, where the cross-linked high amylose starch is cross-linked with phosphorus oxychloride and/or comprises hydroxypropyl side chains. In certain embodiments, the cross-linked high amylose starch comprises between about 65% and 75% by weight amylose and is cross-linked with phosphorus oxychloride. A suitable excipient has been developed by and is available commercially from Labopharm, Inc., Laval, Canada, under the trademark CONTRAMID®. The synthesis of the CONTRAMID® excipient is described, for example, in U.S. Pat. No. 6,607,748, hereby incorporated by reference in its entirety for all purposes. Compositions contemplated herein may include cross-linked high amylose starch together with one or more additional controlled release excipients.
- Cross-linking of starch represents a powerful method for modifying starch. Usually, starch granules are cross-linked to increase resistance of the paste to shear or heat. Such chemically cross-linked starches provide a desirable smooth texture and possess viscosity stability throughout processing operations and normal shelf life. In some embodiments, cross-linked high amylose starch as contemplated herein may be gelatinized after cross-linking. In a preferred embodiment, cross-linking high amylose starch may include additional chemical modification (e.g., hydroxypropylation) prior to gelatinization.
- The cross-linking of high amylose starch may be realized according to procedures described in the art. For example, cross-linking of amylose can be carried out in the manner described in Mateescu [B
IOCHEMIE 60: 535-537 (1978)] by reacting amylose with epichlorohydrin in an alkaline medium. In the same manner, starch can also be cross-linked with a reagent selected from the group consisting of epichlorohydrin, adipic acid anhydride, sodium trimetaphosphate and phosphorous oxychloride or other cross-linking agents including, but not limited to, 2,3-dibromopropanol, linear mixed anhydrides of acetic and di- or tribasic carboxylic acids, vinyl sulfone, diepoxides, cyanuric chloride, hexahydro-1,3,5-trisacryloyl-s-triazine, hexamethylene diisocyanate,toluene 2,4-diisocyanate, N,N-methylenebisacrylamide, N,N′-bis (hydroxymethyl) ethyleneurea, mixed carbonic-carboxylic acid anhydrides, imidazolides of carbonic and polybasic carboxylic acids, imidazolium salts of polybasic carboxylic acids, and guanidine derivatives of polycarboxylic acids. The reaction conditions employed will vary with the type and amount of the cross-linking agent that is used, as well as the base concentration, amount and type of starch. - It is contemplated that starches containing more than about 40% w/w amylose can be used to form cross-linked high amylose starch, e.g., pea and wrinkled pea starch, bean starch, hybrids or genetically modified tapioca or potato starch, or any other root, tuber or cereal starch. Preferably, high amylose starch containing about 70% w/w amylose is used as the base material. For example, high amylose starch, Cerestar AmyloGel 03003 (Cerestar U.S.A. Inc.), may be used.
- It has been discovered that by combining trazodone or a trazodone derivative with a controlled release excipient, for example, cross-linked high amylase starch (for example, CONTRAMID® cross-linked high amylose starch), trazodone, which is pH sensitive with a pKa of about 6.74 can be released and absorbed not only in the upper gastrointestinal tract where the pH is below the pKa of trazodone (where trazodone is soluble) but also in the lower gastrointestinal tract where the pH is above the pKa of trazodone (where trazodone is poorly soluble) thereby maintaining stable plasma concentrations in the blood throughout gastrointestinal transit. To this day, to our knowledge, no once a day formulation including a pH dependent active agent has been suggested or designed for a composition that has the pharmacokinetic profile described herein.
- The pharmaceutical composition according to the invention may also comprise pharmaceutically acceptable additives. Such additives can include, for example, sugars, such as lactose, glucose and sucrose; other starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; and other non-toxic compatible substances employed in pharmaceutical formulations. Such additives may also include colorants.
- For example, the compositions disclosed herein may include any one of a mixture of a binding agent, a solubilizing agent, an acidifying agent, a pore forming agent, a lubricant, a glidant, and the like, as is well known to those skilled in the art. Preferred pharmaceutical additives that are used in providing a composition according to the invention may include, for example, binding agents that include, for example, hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, dicalcium phosphate, calcium phosphate, microcrystalline cellulose, or the like, solubilizing agents that include, for example, povidone, cetylpyridinium chloride, or the like, acidifying agents that include, for example, alginic acid, citric acid, succinic acid, bile acid or the like, pore forming agents, that include, for example, sucrose, lactose, mannitol or the like, lubricants that include, for example, sodium stearyl fumarate, magnesium stearate, calcium stearate, stearic acid, hydrogentated vegetable oils or the like and/or glidants that include, for example, colloidal silicon dioxide, talc or the like. Other additives that are well known to those skilled in the art may of course be included in the composition according to the invention without departing from the scope and spirit of the present invention.
- For example, the composition according to the invention may comprise about 20 to 50 weight percent trazodone hydrochloride, about 20 to 50 weight percent cross-linked high amylase starch (for example, CONTRAMID® cross-linked high amylose starch), about 10 to 25 weight percent hydroxypropylmethylcellulose, about 0 to 10 weight percent cetylpyridinium chloride, about 0 to 20 weight percent alginic acid, about 1 to 5 weight percent sodium stearyl fumarate, and up to about 1 weight percent colloidal silicon dioxide.
- The composition according to the invention is normally prepared in the form of a tablet. Although the tablet can adopt a wide variety of shapes as is well known to those skilled in the art, the preferred shape is a caplet. Such caplets may be formed using, for example, upper and lower punches as is known in the art. In some embodiments, tablets may include a coat, such as, for example, a coating with a colorant. Suitable coatings include, for example, aqueous film coating polymers such as polyvinyl alcohol, talc, macrogol and the like, and mixtures thereof. Suitable colorants include, for example, iron oxides, lakes, natural colorants and other colorants known to those skilled in the art.
- In an exemplary formulation protocol for producing a 5 kg batch of an exemplary sustained release formulation, CONTRAMID® excipient, hydroxypropylmethyl cellulose, trazodone HCl and sodium stearyl fumarate are individually weighed and sifted through a 30 mesh filter. Colloidal silicon dioxide is weighed and pre-blended with CONTRAMID®, sifted through a 30 mesh filter, and blended for 10-30 seconds, for example, 15 seconds to produce a pre-blend. Hydroxypropylmethylcellulose, trazodone and the Contramid®-collodial silicon dioxide pre-blend, are combined and blended for 5-10 minutes, for example, 7 minutes, to produce a bulk blend. A small portion of the resulting bulk blend is combined with the sodium stearyl fumarate and blended for 20-60 seconds, for example, 30 seconds. The resulting sodium stearyl fumarate blend is combined with the residual bulk blend, and the resulting mixture blended for about 2-6 minutes, for example, 4 minutes. The final blend is compressed into tablets using a compression pressure of 27 kN. Caplets are formed using a caplet standard concave punch.
- A dosage for once a day administration may be 25 mg to 600 mg of trazodone or a trazodone derivative. Typical doses for once a day administration include 150 mg or 300 mg of trazodone or a trazodone derivative, although this amount may vary to a large extent depending on required needs, and the specific requirements of the treating physician. For example, the dosage of any compositions of the present invention will vary depending on the symptoms, age and body weight of the patient, the nature and severity of the disorder to be treated or prevented, the route of administration, and the form of the subject composition. Dosages for the compositions of the present invention may be readily determined by techniques known to those of skill in the art or as taught herein. The precise time of administration and amount of any particular subject composition that will yield the most effective treatment in a given patient will depend upon the activity, pharmacokinetics, and bioavailability of a subject composition, physiological condition of the patient (including age, sex, disease type and stage, general physical condition, responsiveness to a given dosage and type of medication), route of administration, and the like. The guidelines presented herein may be used to optimize the treatment, e.g., determining the optimum time and/or amount of administration, which will require no more than routine experimentation consisting of monitoring the subject and adjusting the dosage and/or timing.
- The resulting formulations have in vitro profiles, preferably, as described in Examples 1 and 3, hereinbelow. The in vitro release profiles were measured as follows. Briefly, the release rates were determined using a U.S.P. paddle method (apparatus type II as described in U.S.P. XXVI) at 150 revolutions per minute, at 37±0.5° C., in 900 mL of hydrochloride/sodium chloride pH 1.2 solution (acid stage) followed after one hour by 900 mL of sodium phosphate monobasic buffer pH 6.0 (buffer stage). In some embodiments; formulations may have release kinetics, whereby, when tested by the foregoing method, not more than about 30% of the active ingredient is released by 1 hour after initiation of the experiment, about 35% to 60% of the active ingredient is released by 6 hours, not more than about 80% of the active ingredient is released by 12 hours, and/or not less than about 80% of the active ingredient is released by 24 hours.
- The compositions described herein are particularly useful in treating depression, disorders associated with depression, and sleep disorders. According, a mammal suffering from depression can be administered once a day (for example, at bedtime) with a trazodone formulation as defined above. A mammal to be treated by the subject method may mean either a human or non-human animal.
- The compositions described herein may also be useful in treating patients that have difficulty sleeping and/or have disrupted sleep architecture, i.e., disrupted non-REM/REM stage and cycle infrastructure of sleep. In some embodiments, formulations disclosed herein release a therapeutically effective portion of trazodone within one hour after oral administration and thus rapidly induce somnolence but yet provide substantially no drowsiness in a patient about 8 hours after oral administration as compared to repeat administration of an immediate release trazodone composition. Accordingly, such formulations reduce undesirable drowsiness in waking hours or in the day time.
- The invention will now be illustrated by means of the following examples which are given for the purpose of illustration only and without any intention to limit the scope of the present invention.
- A first
sustained release 300 mg trazodone containing formulation (denoted Formulation 1) was prepared having the composition set forth in TABLE 1. -
TABLE 1 Formulation 1Tablet Tablet Ingredients (mg) % CONTRAMID ® excipient 200 32.7 Trazodone HCl 300 49.0 Hydroxylpropylmethyl cellulose K100M 100 16.3 Colloidal silicon dioxide 3 0.5 Sodium stearyl fumarate 9 1.5 Total 612 100 - The in vitro release kinetics of this formulation were measured using the U.S.P. paddle method (apparatus type II as described in U.S.P. XXVI) at 150 revolutions per minute, at 37±0.5° C., in 900 mL of hydrochloride/sodium chloride pH 1.2 solution (acid stage) followed after one hour by 900 mL of sodium phosphate monobasic buffer pH 6.0 (buffer stage). This formulation, when tested using the foregoing method, had an in vitro release profile where not more than about 30% of the active ingredient was released by 1 hour after initiation of the experiment, about 35% to 55% of the active ingredient was released by 6 hours, not more than 80% of the active ingredient was released by 12 hours, and not less than 80% of the active ingredient was released by 24 hours.
- In addition, the formulation was tested in vivo. The pharmacokinetics of this formulation were compared with those of the commercial products
Trittico® AC 150 mg CR tablets given BID, andDesyrel® 100 mg IR tablets given TID in a human randomized pharmacokinetic crossover study. It was found that following administration ofFormulation 1, trazodone plasma concentrations increased more gradually and peak trazodone plasma concentrations were lower than those of either of the reference products. The mean plasma trazodone concentration measured in 18 patients is shown inFIG. 2 . The results indicate that this formulation provides a therapeutic plasma concentration within about 1 hour and provides a substantially constant trazodone concentration from 1 hour to 24 hours. The trazodone plasma concentrations at 24 hours were similar to those following TID administration of Desyrel® and BID administration of Trittico® AC. - The in vivo experiments demonstrate that following oral administration of
Formulation 1, after a short period to reach acceptable plasma concentrations, trazodone plasma concentrations were maintained at a relatively constant level from approximately 1 hour post-administration to at least 24 hours post-administration. - A second
sustained release 300 mg trazodone containing formulation (denoted Formulation 2) was prepared having the composition set forth in TABLE 2. -
TABLE 2 Formulation 2Tablet Tablet Ingredients (mg) % CONTRAMID ® excipient 169 24.1 Trazodone HCl 300 24.1 Hydroxypropylmethyl cellulose K110M 105 15.0 Alginic acid 105 15.0 Cetylpyridinium chloride 7 1.0 Colloidal silicon dioxide 3.5 0.5 Sodium stearyl fumarate 10.5 1.5 Total 700 10 - The in vitro release kinetics of
Formulation 2 were measured using the U.S.P. paddle method as described in Example 1. The in vitro dissolution profile (FIG. 3 ) shows that in this formulation, not more than about 30% of the active ingredient was released by 1 hour after initiation of the experiment, about 35% to 55% of the active ingredient was released by 6 hours, not more than 80% of the active ingredient was released by 12 hours, and not less than 80% of the active ingredient was released by 24 hours -
Formulation 2 was also evaluated in vivo. The results obtained were substantially the same whenFormulation 2 was compared with Trittico® AC and Desyrel®. The mean plasma trazodone concentration measured in 19 patients is shown inFIG. 4 . It was found that following administration ofFormulation 2, trazodone plasma concentrations increased to provide a therapeutic concentration in about 1 hour. The plasma concentrations increased till about 6 hours after oral administration but then gradually declined. The plasma concentration of trazodone provided byFormulation 1 was more stable between 1 hours and 24 hours than that provided byFormulation 2. - A first
sustained release 150 mg trazodone containing formulation (denoted Formulation 3) was prepared having the composition set forth in TABLE 3. -
TABLE 3 Formulation 3 Tablet Tablet Ingredients (mg) % CONTRAMID ® excipient 252 46.8 Trazodone HCl 150 27.8 Hydroxypropylmethylcellulose K100M 126 23.4 Colloidal silicon dioxide 3 0.5 Sodium stearyl fumarate 8 1.5 Total 540 100 - The in vitro release kinetics of Formulation 3 were measured using the U.S.P. paddle method as described in Example 1. The in vitro dissolution profile (
FIG. 5 ) shows that in this formulation, not more than about 30% of the active ingredient was released by 1 hour after initiation of the experiment, about 40% to 60% of the active ingredient was released by 6 hours, not more than 80% of the active ingredient was released by 12 hours, and not less than 80% of the active ingredient was released by 24 hours. -
Formulation 2 was also evaluated in vivo. The mean plasma trazodone concentration measured in 18 patients is shown inFIG. 6 . It was found that following administration of Formulation 3, trazodone plasma concentrations increased rapidly to provide a therapeutic concentration in about 1 hour. The results indicate a substantially constant trazodone concentration from 1 hour to 24 hours. As withformulation 1, this appears to show zero order release kinetics between 1 hour and 24 hours following oral administration. - The entire disclosure of each of the documents referred to herein is incorporated by reference for all purposes.
- Although the present invention has been illustrated by means of preferred embodiments thereof, it is understood that the invention intends to cover broad aspects thereof without departing from the spirit and scope of the invention as defined in the appended claims.
Claims (30)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/892,466 US20110015205A1 (en) | 2005-09-09 | 2010-09-28 | Trazodone Composition for Once a Day Administration |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71516205P | 2005-09-09 | 2005-09-09 | |
US11/519,194 US7829120B2 (en) | 2005-09-09 | 2006-09-11 | Trazodone composition for once a day administration |
US12/892,466 US20110015205A1 (en) | 2005-09-09 | 2010-09-28 | Trazodone Composition for Once a Day Administration |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/519,194 Continuation US7829120B2 (en) | 2005-09-09 | 2006-09-11 | Trazodone composition for once a day administration |
Publications (1)
Publication Number | Publication Date |
---|---|
US20110015205A1 true US20110015205A1 (en) | 2011-01-20 |
Family
ID=37968167
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/519,189 Active 2030-08-01 US8795723B2 (en) | 2005-09-09 | 2006-09-11 | Sustained drug release compositions |
US11/519,194 Active 2027-03-27 US7829120B2 (en) | 2005-09-09 | 2006-09-11 | Trazodone composition for once a day administration |
US12/892,454 Active 2029-06-06 US9439866B2 (en) | 2005-09-09 | 2010-09-28 | Trazodone composition for once a day administration |
US12/892,466 Abandoned US20110015205A1 (en) | 2005-09-09 | 2010-09-28 | Trazodone Composition for Once a Day Administration |
US12/905,577 Active 2026-09-21 US8962019B2 (en) | 2005-09-09 | 2010-10-15 | Sustained drug release composition |
US12/905,567 Active 2026-10-09 US8414919B2 (en) | 2005-09-09 | 2010-10-15 | Sustained drug release composition |
US14/628,971 Abandoned US20150306041A1 (en) | 2005-09-09 | 2015-02-23 | Sustained drug release composition |
US15/093,468 Abandoned US20160361262A1 (en) | 2005-09-09 | 2016-04-07 | Sustained drug release composition |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/519,189 Active 2030-08-01 US8795723B2 (en) | 2005-09-09 | 2006-09-11 | Sustained drug release compositions |
US11/519,194 Active 2027-03-27 US7829120B2 (en) | 2005-09-09 | 2006-09-11 | Trazodone composition for once a day administration |
US12/892,454 Active 2029-06-06 US9439866B2 (en) | 2005-09-09 | 2010-09-28 | Trazodone composition for once a day administration |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/905,577 Active 2026-09-21 US8962019B2 (en) | 2005-09-09 | 2010-10-15 | Sustained drug release composition |
US12/905,567 Active 2026-10-09 US8414919B2 (en) | 2005-09-09 | 2010-10-15 | Sustained drug release composition |
US14/628,971 Abandoned US20150306041A1 (en) | 2005-09-09 | 2015-02-23 | Sustained drug release composition |
US15/093,468 Abandoned US20160361262A1 (en) | 2005-09-09 | 2016-04-07 | Sustained drug release composition |
Country Status (23)
Country | Link |
---|---|
US (8) | US8795723B2 (en) |
EP (2) | EP1940467B1 (en) |
JP (3) | JP5269595B2 (en) |
KR (2) | KR101655455B1 (en) |
CN (2) | CN101252932B (en) |
AR (1) | AR109571A2 (en) |
AU (2) | AU2006308449B8 (en) |
BR (1) | BRPI0615860B8 (en) |
CA (2) | CA2616416A1 (en) |
DK (2) | DK1931346T3 (en) |
EA (1) | EA014739B1 (en) |
EC (2) | ECSP088240A (en) |
ES (2) | ES2389666T3 (en) |
HK (1) | HK1124237A1 (en) |
IL (2) | IL188964A0 (en) |
NO (2) | NO20081593L (en) |
NZ (1) | NZ565591A (en) |
PL (1) | PL1931346T3 (en) |
PT (1) | PT1931346E (en) |
RU (1) | RU2008113439A (en) |
UA (1) | UA94916C2 (en) |
WO (2) | WO2007048220A2 (en) |
ZA (2) | ZA200801158B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070128269A1 (en) * | 2005-09-09 | 2007-06-07 | Sonia Gervais | Sustained drug release compositions |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8487002B2 (en) * | 2002-10-25 | 2013-07-16 | Paladin Labs Inc. | Controlled-release compositions |
TWI319713B (en) * | 2002-10-25 | 2010-01-21 | Sustained-release tramadol formulations with 24-hour efficacy | |
CA2533150C (en) * | 2003-07-25 | 2013-03-12 | Warner Chilcott Company, Inc. | A doxycycline metal complex in a solid dosage form |
US20060172006A1 (en) * | 2003-10-10 | 2006-08-03 | Vincent Lenaerts | Sustained-release tramadol formulations with 24-hour clinical efficacy |
JP5235416B2 (en) * | 2005-01-21 | 2013-07-10 | ワーナー・チルコット・カンパニー・エルエルシー | Tetracycline metal complexes in solid dosage forms. |
ITMI20071603A1 (en) * | 2007-08-03 | 2009-02-04 | Acraf | TRAZODONE AND CHLORIDATED TRAZODONE IN PURIFIED FORM |
CN105534936B (en) * | 2007-08-13 | 2020-07-31 | Ohemo 生命科学股份有限公司 | Abuse resistant drugs, methods of use and methods of preparation |
RU2469718C2 (en) * | 2007-10-16 | 2012-12-20 | Лабофарм Инк. | Two-layer composition for continuous release of acetaminophen and tramadol |
JP5651818B2 (en) | 2007-12-17 | 2015-01-14 | パラディン ラブス インコーポレーテッド | Controlled release formulation to prevent misuse |
FR2928836B1 (en) * | 2008-03-21 | 2011-08-26 | Servier Lab | SECURE GALENIC FORM FOR MODIFIED RELEASE OF THE ACTIVE INGREDIENT |
MY161550A (en) * | 2008-10-27 | 2017-04-28 | Alza Corp | Extended release oral acetaminophen/tramadol dosage form |
US8486449B2 (en) | 2008-12-16 | 2013-07-16 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
EP2379069B1 (en) * | 2008-12-22 | 2015-03-04 | Novartis AG | Dosage regimen of an s1p receptor agonist |
WO2012072665A1 (en) | 2010-11-30 | 2012-06-07 | Pharmaneuroboost N.V. | Compositions comprising pipamperone and serotonin antagonist reuptake inhibitors |
US9114902B2 (en) | 2011-03-22 | 2015-08-25 | Polyone Designed Structures And Solutions Llc | Methods and systems for use in forming an article from a multi-layer sheet structure |
CN102935074B (en) * | 2011-08-15 | 2015-04-22 | 成都康弘药业集团股份有限公司 | Trazodone hydrochloride osmotic pump controlled release tablet |
EP2581773A1 (en) * | 2011-10-14 | 2013-04-17 | Astrium Limited | Device with Quantum Well Layer |
EP2872121B1 (en) | 2012-07-12 | 2018-09-05 | SpecGx LLC | Extended release, abuse deterrent pharmaceutical compositions |
PL2919903T3 (en) | 2012-11-14 | 2020-12-14 | W.R. Grace & Co. - Conn. | Compositions containing a biologically active material and a non-ordered inorganic oxide |
BR112015021002B8 (en) * | 2013-03-15 | 2023-03-28 | Mallinckrodt Llc | SOLID PHARMACEUTICAL DOSAGE FORM COMPRISING AN ACTIVE PHARMACEUTICAL INGREDIENT |
US11571390B2 (en) | 2013-03-15 | 2023-02-07 | Othemo Life Sciences, Inc. | Abuse deterrent compositions and methods of use |
WO2014167440A1 (en) * | 2013-03-26 | 2014-10-16 | Wockhardt Limited | Modified release pharmaceutical compositions of cyclobenzaprine or salts thereof |
WO2015060935A1 (en) | 2013-10-22 | 2015-04-30 | Lubris, Llc | Control of rheological properties of mixed hyaluronate/lubricin solutions |
US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
US10729685B2 (en) | 2014-09-15 | 2020-08-04 | Ohemo Life Sciences Inc. | Orally administrable compositions and methods of deterring abuse by intranasal administration |
CN104784738B (en) * | 2015-04-03 | 2016-12-07 | 四川大学 | A kind of natural slow release multiple-effect medical sponge |
EP3317281B1 (en) | 2015-07-02 | 2020-04-22 | Acerta Pharma B.V. | Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide |
CN105708796A (en) * | 2016-03-24 | 2016-06-29 | 深圳市泛谷药业股份有限公司 | Sustained release preparation containing trazodone hydrochloride oral solution and preparation method of sustained release preparation |
CN105748421B (en) * | 2016-03-24 | 2019-03-08 | 深圳市泛谷药业股份有限公司 | A kind of sustained release tablets and preparation method thereof of hydrochloric Trazodone |
GB2567493B (en) * | 2017-10-13 | 2019-12-18 | Altus Formulation Inc | Starch-based release modifying excipients and pharmaceutical compositions derived therefrom |
WO2019089330A1 (en) | 2017-11-01 | 2019-05-09 | Edgemont Pharmceuticals, Llc Trust | Alcohol-resistant oral pharmaceutical compositions of lorazepam |
EP3501503A1 (en) * | 2017-12-22 | 2019-06-26 | Cosmo Technologies Ltd. | Solid delivery composition |
RU2706700C1 (en) * | 2019-09-24 | 2019-11-20 | Общество с ограниченной ответственностью "Научно-производственная компания "СКиФФ" | Pharmaceutical composition for correcting behavior of cats and dogs in stress situations |
BR112022018572A2 (en) | 2020-03-16 | 2022-11-01 | Gruenenthal Gmbh | GROOVED TABLET |
US20230115209A1 (en) * | 2020-03-20 | 2023-04-13 | Orthogonal Thinker, Inc. | Psilocybin and psilocin containing compositions and methods of using and making the same |
Citations (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2987445A (en) * | 1958-10-10 | 1961-06-06 | Rohm & Haas | Drug composition |
US3087860A (en) * | 1958-12-19 | 1963-04-30 | Abbott Lab | Method of prolonging release of drug from a precompressed solid carrier |
US3336200A (en) * | 1963-05-28 | 1967-08-15 | Warner Lambert Pharmaceutical | Tablet structure |
US3381009A (en) * | 1965-12-15 | 1968-04-30 | Acraf | Triazole-(4,3-a)-pyridines |
US3652589A (en) * | 1967-07-27 | 1972-03-28 | Gruenenthal Chemie | 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols |
US4595587A (en) * | 1983-04-18 | 1986-06-17 | Boehringer Ingelheim Kg | Divisible pharmaceutical tablet with delayed active ingredient release |
US4820522A (en) * | 1987-07-27 | 1989-04-11 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
US4824677A (en) * | 1986-12-18 | 1989-04-25 | The Unjohn Company | Grooved tablet for fractional dosing of sustained release medication |
US4906632A (en) * | 1987-12-02 | 1990-03-06 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F.S | Method of preventing myocardial infarction and acute cerebral ischaemia |
US4938968A (en) * | 1988-07-26 | 1990-07-03 | Norjec Development Associates, Inc. | Controlled release indomethacin |
US5004613A (en) * | 1987-07-27 | 1991-04-02 | Mcneil-Ppc, Inc. | Oral sustained release pharmaceutical formulation and process |
US5126145A (en) * | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
US5132116A (en) * | 1987-07-16 | 1992-07-21 | Pierre Fabre Medicament | Tablets of the hydrophilic matrix type based on salbutamol and a process for their preparation |
US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5286493A (en) * | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
US5336691A (en) * | 1991-09-06 | 1994-08-09 | Mcneilab, Inc. | Composition comprising a tramadol material and acetaminophen and its use |
US5407686A (en) * | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
US5414129A (en) * | 1992-09-08 | 1995-05-09 | Chemagis, Ltd. | Process for the purification of 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol and its salts |
US5427799A (en) * | 1992-03-25 | 1995-06-27 | Valentine Enterprises, Inc. | Sustained release composition and method utilizing xanthan gum and an active ingredient |
US5520931A (en) * | 1992-07-29 | 1996-05-28 | Gacell Laboratories Ab | Controlled release morphine preparation |
US5591452A (en) * | 1993-05-10 | 1997-01-07 | Euro-Celtique, S.A. | Controlled release formulation |
US5595762A (en) * | 1992-11-30 | 1997-01-21 | Laboratoires Virbac | Stabilized pulverulent active agents, compositions containing them, process for obtaining them and their applications |
US5601842A (en) * | 1993-09-03 | 1997-02-11 | Gruenenthal Gmbh | Sustained release drug formulation containing a tramadol salt |
US5603956A (en) * | 1990-11-27 | 1997-02-18 | Labopharm Inc. | Cross-linked enzymatically controlled drug release |
US5616343A (en) * | 1993-03-25 | 1997-04-01 | Labopharm, Inc. | Cross-linked amylose as a binder/disintegrant in tablets |
US5639476A (en) * | 1992-01-27 | 1997-06-17 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5773031A (en) * | 1996-02-27 | 1998-06-30 | L. Perrigo Company | Acetaminophen sustained-release formulation |
US5776492A (en) * | 1995-08-19 | 1998-07-07 | Gruenenthal Gmbh | Rapidly disintegrating medicinal form of tramadol or a tramadol salt |
US5780057A (en) * | 1996-02-19 | 1998-07-14 | Jagotec Ag | Pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids |
US5874620A (en) * | 1996-08-22 | 1999-02-23 | Chemagis, Ltd. | Process for the purification of (RR-SS)-2-dimethylaminomethyl-1-(3-methoxyphenyl)cyclohexanol hydrochloride |
US5877351A (en) * | 1997-12-24 | 1999-03-02 | Wyckoff Chemical Company, Inc. | Preparation and purification process for 2- (dimethylamino) methyl!-1-(3-methoxphenyl)-cyclohexanol and its salts |
US5879707A (en) * | 1996-10-30 | 1999-03-09 | Universite De Montreal | Substituted amylose as a matrix for sustained drug release |
US5879705A (en) * | 1993-07-27 | 1999-03-09 | Euro-Celtique S.A. | Sustained release compositions of morphine and a method of preparing pharmaceutical compositions |
US5885615A (en) * | 1996-04-10 | 1999-03-23 | Labopharm Inc. | Pharmaceutical controlled release tablets containing a carrier made of cross-linked amylose and hydroxypropylmethylcellulose |
US5888545A (en) * | 1994-07-01 | 1999-03-30 | Arzneimittelwerk Dresden Gmbh | Carbamazepine medicament with retarded active substance release |
US5891471A (en) * | 1993-11-23 | 1999-04-06 | Euro-Celtique, S.A. | Pharmaceutical multiparticulates |
US6103261A (en) * | 1993-07-01 | 2000-08-15 | Purdue Pharma Lp | Opioid formulations having extended controlled release |
US6190591B1 (en) * | 1996-10-28 | 2001-02-20 | General Mills, Inc. | Embedding and encapsulation of controlled release particles |
US6210714B1 (en) * | 1993-11-23 | 2001-04-03 | Euro-Celtique S.A. | Immediate release tablet cores of acetaminophen having sustained-release coating |
US6211229B1 (en) * | 2000-02-17 | 2001-04-03 | Neil B. Kavey | Treatment of transient and short term insomnia |
US6214331B1 (en) * | 1995-06-06 | 2001-04-10 | C. R. Bard, Inc. | Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained |
US6228875B1 (en) * | 1998-04-14 | 2001-05-08 | The General Hospital Corporation | Methods for treating neuropsychiatric disorders |
US6245356B1 (en) * | 1993-09-09 | 2001-06-12 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems-amorphous drugs |
US6245387B1 (en) * | 1998-11-03 | 2001-06-12 | Diamon-Fusion International, Inc. | Capped silicone film and method of manufacture thereof |
US6245357B1 (en) * | 1998-03-06 | 2001-06-12 | Alza Corporation | Extended release dosage form |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6254881B1 (en) * | 1996-12-18 | 2001-07-03 | Bimeda Research & Development Limited | Antiinfective free intramammary veterinary composition |
US6261599B1 (en) * | 1994-11-04 | 2001-07-17 | Euro-Celtique, S.A. | Melt-extruded orally administrable opioid formulations |
US6339105B1 (en) * | 1999-10-12 | 2002-01-15 | Ortho-Mcneil Pharmaceutical, Inc. | Analgesic regimen |
US20020008133A1 (en) * | 2000-06-14 | 2002-01-24 | Katsuhiro Imasaki | Two-layer clad pipe and method for making the same |
US20020012701A1 (en) * | 2000-06-19 | 2002-01-31 | Karl Kolter | Process for producing solid oral dosage forms with sustained release of active ingredient |
US20020032239A1 (en) * | 2000-02-21 | 2002-03-14 | Gruenenthal Gmbh | Use of O-desmethyl-N-mono-desmethyl-tramadol |
US6372255B1 (en) * | 1997-12-23 | 2002-04-16 | Merck Patent Gesellschaft | Tablet for instant and prolonged release of one or more active substances |
US20020044966A1 (en) * | 1999-01-18 | 2002-04-18 | Johannes Bartholomaeus | Pharmaceutical formulations containing an opioid and an alpha-agonist |
US20020052411A1 (en) * | 1998-09-03 | 2002-05-02 | Dagmar Gobel | Valproate compositions and processes for making |
US6399096B1 (en) * | 1995-09-22 | 2002-06-04 | Euro-Celtique S.A. | Pharmaceutical formulation |
US6419957B1 (en) * | 1998-02-24 | 2002-07-16 | Labopharm, Inc. | Cross-linked high amylose starch having functional groups as a matrix for the slow release of pharmaceutical agents |
US20030021846A1 (en) * | 2000-03-27 | 2003-01-30 | Karl Kolter | Active ingredient-containing floating forms comprising polyvinyl acetate and polyvinylpyrrolidone, their use and production |
US20030035835A1 (en) * | 1999-08-31 | 2003-02-20 | Johannes Bartholomaeus | Sustained-release form of administration containing tramadol saccharinate |
US20030035837A1 (en) * | 1993-11-23 | 2003-02-20 | Sackler Richard S. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US20030044464A1 (en) * | 1999-08-31 | 2003-03-06 | Iris Ziegler | Sustained-release, oral pharamaceutical forms of formulation |
US20030054032A1 (en) * | 1991-12-24 | 2003-03-20 | Benjamin Oshlack | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US20030069314A1 (en) * | 1999-10-05 | 2003-04-10 | Gruenenthal Gmbh | Use of (+)-tramadol, O-demethyltramadol or (+)-O-demethyl-tramadol, O-desmethyl-N-mono-desmethyl-tramadol or (+)- O-desmethyl-N-mono-desmethyltramadol for the treatment of urinary incontinence |
US20030068371A1 (en) * | 2001-08-06 | 2003-04-10 | Benjamin Oshlack | Pharmaceutical formulation containing opioid agonist,opioid antagonist and gelling agent |
US20030068375A1 (en) * | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
US6558701B2 (en) * | 1999-06-17 | 2003-05-06 | Gruenenthal Gmbh | Multilayer tablet for administering a fixed combination of tramadol and diclofenac |
US20030092724A1 (en) * | 2001-09-18 | 2003-05-15 | Huaihung Kao | Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic |
US6572885B2 (en) * | 1991-12-24 | 2003-06-03 | Euro-Celtique, S.A. | Orally administrable opioid formulations having extended duration of effect |
US20030104061A1 (en) * | 1999-01-18 | 2003-06-05 | Gruenenthal Gmbh | Controlled release tramadol preparations with a storage-stable release profile and process for their production |
US6586006B2 (en) * | 1994-08-04 | 2003-07-01 | Elan Drug Delivery Limited | Solid delivery systems for controlled release of molecules incorporated therein and methods of making same |
US20030143270A1 (en) * | 2001-04-11 | 2003-07-31 | Galephar Pharmaceutical Research, Inc. | Extended release composition containing Tramadol |
US6685964B1 (en) * | 1999-01-18 | 2004-02-03 | Gruenenthal Gmbh | Opioid analgesics with controlled active substance release |
US6723343B2 (en) * | 1999-08-31 | 2004-04-20 | Gruenenthal Gmbh | Pharmaceutical tramadol salts |
US6733783B2 (en) * | 2000-10-30 | 2004-05-11 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
US20040131671A1 (en) * | 2002-09-21 | 2004-07-08 | Shuyi Zhang | Sustained release formulations containing acetaminophen and tramadol |
US20040136924A1 (en) * | 2002-12-30 | 2004-07-15 | Boyd Thomas J. | Oral care compositions and methods |
US6863901B2 (en) * | 2001-11-30 | 2005-03-08 | Collegium Pharmaceutical, Inc. | Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration |
US20050157382A1 (en) * | 2004-01-07 | 2005-07-21 | Kafka James D. | Industrial directly diode-pumped ultrafast amplifier system |
EP1576986A2 (en) * | 2003-10-10 | 2005-09-21 | Labopharm Inc. | Sustained-release tramadol formulations with 24-hour clinical efficacy |
US20060009465A1 (en) * | 2002-01-18 | 2006-01-12 | Dale Edgar | Treatment of sleep disorders using sleep target modulators |
US20060111307A1 (en) * | 2004-11-16 | 2006-05-25 | Wendye Robbins | Methods and compositions for treating pain |
US20060115530A1 (en) * | 2002-10-16 | 2006-06-01 | Anders Pettersson | Gastric acid secretion inhibiting composition |
US20070003618A1 (en) * | 2002-10-25 | 2007-01-04 | Vincent Lenaerts | Sustained-release tramadol formulations with 24-hour efficacy |
US20070048376A1 (en) * | 2005-08-24 | 2007-03-01 | Penwest Pharmaceuticals Co. | Sustained release formulations of nalbuphine |
US20070128269A1 (en) * | 2005-09-09 | 2007-06-07 | Sonia Gervais | Sustained drug release compositions |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US338109A (en) * | 1886-03-16 | Clothes-fork | ||
GB1368574A (en) | 1971-02-12 | 1974-10-02 | Ives Lab Inc | Divisible tablet |
US4131675A (en) | 1978-02-09 | 1978-12-26 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Use of combinations of L-DOPA with trazodone and L-DOPA with etoperidone in Parkinsonism |
US4344554A (en) * | 1978-10-02 | 1982-08-17 | Xerox Corporation | Stapling apparatus |
US4353887A (en) | 1979-08-16 | 1982-10-12 | Ciba-Geigy Corporation | Divisible tablet having controlled and delayed release of the active substance |
US4465660A (en) | 1981-04-01 | 1984-08-14 | Mead Johnson & Company | Sustained release tablet containing at least 95 percent theophylline |
US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
CA2041774C (en) | 1990-11-27 | 1994-04-19 | Mircea A. Mateescu | Use of cross-linked amylose as a matrix for the slow release of biologically active compounds |
JPH0719339Y2 (en) | 1991-10-07 | 1995-05-10 | 東ポリ株式会社 | Wire clothes hangers |
GB2284760B (en) | 1993-11-23 | 1998-06-24 | Euro Celtique Sa | A method of preparing pharmaceutical compositions by melt pelletisation |
US5273760A (en) | 1991-12-24 | 1993-12-28 | Euroceltigue, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5958459A (en) | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
FR2688422A1 (en) | 1992-03-11 | 1993-09-17 | Coletica | MICROCAPSULES WITH POLYSACCHARIDE WALLS CONTAINING PRIMARY ALCOHOL FUNCTIONS, AND COMPOSITIONS CONTAINING SAME. |
NZ254048A (en) | 1992-07-24 | 1995-09-26 | Labopharm Inc | Solid controlled release pharmaceutical composition comprising cross linked amylose |
DE4315525B4 (en) | 1993-05-10 | 2010-04-15 | Euro-Celtique S.A. | Pharmaceutical composition |
IL109944A (en) | 1993-07-01 | 1998-12-06 | Euro Celtique Sa | Sustained release dosage unit forms containing morphine and a method of preparing these sustained release dosage unit forms |
AU673775B2 (en) * | 1993-08-24 | 1996-11-21 | Great Lakes Chemical Corporation | Ophthalmic lenses |
JPH0719339U (en) * | 1993-09-07 | 1995-04-07 | 武田薬品工業株式会社 | Split tablet |
US5451409A (en) | 1993-11-22 | 1995-09-19 | Rencher; William F. | Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends |
KR100354702B1 (en) | 1993-11-23 | 2002-12-28 | 유로-셀티크 소시에떼 아노뉨 | Manufacturing method and sustained release composition of pharmaceutical composition |
ES2168290T3 (en) | 1993-11-23 | 2002-06-16 | Euro Celtique Sa | METHOD FOR PREPARING A SUSTAINED RELEASE COMPOSITION. |
US5843480A (en) | 1994-03-14 | 1998-12-01 | Euro-Celtique, S.A. | Controlled release diamorphine formulation |
US5560331A (en) | 1994-05-10 | 1996-10-01 | Yamaha Hatsudoki Kabushiki Kaisha | Cylinder head for engine |
GB2290965A (en) | 1994-07-11 | 1996-01-17 | Therapicon Srl | Multiple layer capsules for drugs |
US6156343A (en) * | 1994-12-27 | 2000-12-05 | Akzo Nobel N.V. | Controlled release preparation |
JP4072597B2 (en) * | 1994-12-27 | 2008-04-09 | ナムローゼ・フェンノートシャップ・オルガノン | Sustained formulation |
US5981592A (en) | 1995-03-13 | 1999-11-09 | Loma Linda University Medical Center | Method and composition for treating cystic fibrosis |
IL116281A (en) * | 1995-12-07 | 1999-06-20 | Chemagis Ltd | Process for the purification of (rr,ss)-2-dimethylaminomethyl-1-(3-methoxyphenyl) cyclohexanol and its salts |
DE19607296A1 (en) * | 1996-02-27 | 1997-08-28 | Kodak Ag | Stitching device for fastening stack-shaped sheets |
JPH1095801A (en) * | 1996-09-24 | 1998-04-14 | Asahi Chem Ind Co Ltd | Cellulose powder having high moldability |
DE19640062B4 (en) | 1996-09-28 | 2006-04-27 | Lts Lohmann Therapie-Systeme Ag | Oral preparation comprising in a matrix swellable in an aqueous medium at least one pharmaceutical active substance |
US5807575A (en) | 1997-02-14 | 1998-09-15 | Rougier Inc. | Manufacture of cross-linked amylose useful as a excipient for control release of active compounds |
EP0969818B1 (en) | 1997-03-11 | 2004-09-08 | Arakis Ltd. | Dosage forms comprising separate portions of r- and s-enantiomers |
DE19710008A1 (en) | 1997-03-12 | 1998-09-17 | Basf Ag | Solid, at least two-phase formulations of a sustained-release opioid analgesic |
BE1011045A3 (en) * | 1997-03-14 | 1999-04-06 | Ucb Sa | Pharmaceutical composition for controlled release of active substances. |
AU7501398A (en) | 1997-05-21 | 1998-12-11 | Warner-Lambert Company | Non-sedating acrivastine preparation |
PT1009387E (en) | 1997-07-02 | 2006-08-31 | Euro Celtique Sa | STABILIZED CONTROLLED FREQUENCY FORMULATIONS OF TRAMADOL |
ES2234139T3 (en) | 1997-08-11 | 2005-06-16 | Alza Corporation | DOSAGE FORM OF AN ACTIVE PROLONGED RELEASE AGENT ADAPTED FOR GASTRIC RETENTION. |
EP0912020A3 (en) * | 1997-10-25 | 2002-07-03 | Alcatel | Decision method with adaptive thresholds |
AU2483599A (en) | 1998-01-29 | 1999-08-16 | Sepracor, Inc. | Pharmaceutical uses of optically pure (-)-bupropion |
US6156342A (en) | 1998-05-26 | 2000-12-05 | Andex Pharmaceuticals, Inc. | Controlled release oral dosage form |
US6143325A (en) | 1998-06-05 | 2000-11-07 | Bristol-Myers Squibb Company | Nefazodone dosage form |
EP1089734A2 (en) * | 1998-06-26 | 2001-04-11 | Georgetown University Medical Center | Use of tempo and tempo derivatives for inducing cell death |
US6632640B1 (en) | 1998-07-10 | 2003-10-14 | The United States Of America As Represented By The Secretary Of The Army | Vaccine against Staphylococcus intoxication |
US6806294B2 (en) | 1998-10-15 | 2004-10-19 | Euro-Celtique S.A. | Opioid analgesic |
WO2000025769A1 (en) | 1998-11-02 | 2000-05-11 | Ortho-Mcneil Pharmaceutical, Inc. | Analgesic regimen |
PL347542A1 (en) | 1998-12-02 | 2002-04-08 | Darwin Discovery Ltd | Therapeutic product and its use |
US6129205A (en) | 1998-12-09 | 2000-10-10 | Ashworth Bros. Inc. | Variable loop count conveyor belt |
US6498196B1 (en) | 1998-12-22 | 2002-12-24 | Edward Roberts | Compounds useful in pain management |
DE19901683B4 (en) | 1999-01-18 | 2005-07-21 | Grünenthal GmbH | Controlled-release analgesic |
US7450229B2 (en) * | 1999-01-25 | 2008-11-11 | Amnis Corporation | Methods for analyzing inter-cellular phenomena |
MXPA01007463A (en) | 1999-01-29 | 2002-06-04 | Losan Pharma Gmbh | Pharmaceutical compositions. |
DE10023699A1 (en) | 1999-08-31 | 2001-04-19 | Gruenenthal Gmbh | Retarded release tramadol dosage form, useful e.g. for treating pain, coughs or urinary incontinence, comprising tramadol saccharinate in retarding coating, e.g. of poly(meth)acrylate |
DE19947747A1 (en) | 1999-10-05 | 2001-04-12 | Gruenenthal Gmbh | Treatment of urinary incontinence using (+)-tramadol, O-demethyl-tramadol or O-demethyl-N-mono-desmethyl-tramadol, having strong effect on bladder function without side-effects or analgesic action |
AU2276801A (en) | 1999-12-20 | 2001-07-03 | Schering Corporation | Extended release oral dosage composition |
US6645537B2 (en) | 2000-02-18 | 2003-11-11 | Keurig, Incorporated | Beverage filter cartridge |
GB0007419D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Gmbh | Composition |
DE10015479A1 (en) | 2000-03-29 | 2001-10-11 | Basf Ag | Solid oral dosage forms with delayed release of active ingredient and high mechanical stability |
GB0009522D0 (en) | 2000-04-19 | 2000-06-07 | Smithkline Beecham Plc | Composition |
US6955821B2 (en) | 2000-04-28 | 2005-10-18 | Adams Laboratories, Inc. | Sustained release formulations of guaifenesin and additional drug ingredients |
US6607748B1 (en) * | 2000-06-29 | 2003-08-19 | Vincent Lenaerts | Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture |
ATE274906T1 (en) | 2000-09-22 | 2004-09-15 | Smb Technology | ORAL PARTICLES CONTAINING TRAMADOL FOR ONCE DAILY ADMINISTRATION |
US20020106408A1 (en) * | 2000-12-01 | 2002-08-08 | Johnatan Bacon | Prolamin-based sustained-release compositions and delayed-onset compositions |
US6287599B1 (en) | 2000-12-20 | 2001-09-11 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
PL201766B1 (en) | 2001-01-31 | 2009-05-29 | Roehm Gmbh | Multi-particulate form of medicament, comprising at least two differently coated forms of pellet |
WO2002069974A1 (en) * | 2001-03-05 | 2002-09-12 | Andrew Holman | Administration of sleep restorative agents |
US6806293B1 (en) | 2001-03-12 | 2004-10-19 | Darley Pharmaceuticals Ltd | Use of pheromone compounds having MAP kinase modulating activity |
US6659373B1 (en) | 2001-05-30 | 2003-12-09 | L. R. Nelson | One touch actuated valve |
US6968551B2 (en) | 2001-06-11 | 2005-11-22 | John Hediger | System and user interface for generation and processing of software application installation instructions |
AU2002351798A1 (en) | 2001-10-29 | 2003-05-12 | Labopharm Inc. | Methods and dosage forms for improving the bioavailability of therapeutic agents |
KR100540035B1 (en) * | 2002-02-01 | 2005-12-29 | 주식회사 태평양 | Multi-stage oral drug controlled-release system |
CA2476201C (en) | 2002-02-21 | 2009-09-01 | Biovail Laboratories Incorporated | Modified release formulations of at least one form of tramadol |
WO2003080031A1 (en) | 2002-03-22 | 2003-10-02 | Cilag Ag | Sustained release formulation of tramadol |
EP1513533B1 (en) * | 2002-05-24 | 2010-03-17 | Carl-Fr. Coester | Pharmaceutical active substance combination and the use thereof |
US7562089B2 (en) * | 2002-06-26 | 2009-07-14 | Seagate Technology Llc | Systems and methods for storing information to allow users to manage files |
FR2841717B1 (en) | 2002-06-28 | 2004-09-10 | Bouygues Telecom Sa | METHOD FOR ENTERING MESSAGES |
CA2503361C (en) * | 2002-10-25 | 2012-02-28 | Labopharm Inc. | Controlled-release compositions |
US8487002B2 (en) | 2002-10-25 | 2013-07-16 | Paladin Labs Inc. | Controlled-release compositions |
JP2006507277A (en) * | 2002-10-25 | 2006-03-02 | ラボファーマ インコーポレイテッド | 24 hour sustained release tramadol formulation |
US7413749B2 (en) | 2003-03-11 | 2008-08-19 | Purdue Pharma L.P. | Titration dosing regimen for controlled release tramadol |
WO2004082684A1 (en) * | 2003-03-17 | 2004-09-30 | Acorda Therapeutics | Stable oral formulations of aminopyridines and uses thereof |
US8007826B2 (en) | 2003-12-11 | 2011-08-30 | Acorda Therapeutics, Inc. | Sustained release aminopyridine composition |
WO2006069293A2 (en) | 2004-12-22 | 2006-06-29 | Friedman Robert S | Composition comprising n-acetylcysteine and further pain or anti- inflamm medications |
US20060228413A1 (en) | 2005-02-28 | 2006-10-12 | Penwest Pharmaceuticals Co. | Controlled release venlafaxine formulations |
US20070237816A1 (en) | 2006-04-06 | 2007-10-11 | David Finkelstein | Acetaminophen formulation for joint pain relief |
WO2010019279A1 (en) | 2008-08-12 | 2010-02-18 | Abuse Deterrent Pharmaceutical Llc | Pharmaceutical compositions configured to deter dosage form splitting |
FR2928836B1 (en) | 2008-03-21 | 2011-08-26 | Servier Lab | SECURE GALENIC FORM FOR MODIFIED RELEASE OF THE ACTIVE INGREDIENT |
-
2006
- 2006-09-11 CA CA002616416A patent/CA2616416A1/en not_active Abandoned
- 2006-09-11 ZA ZA200801158A patent/ZA200801158B/en unknown
- 2006-09-11 EP EP06790660.2A patent/EP1940467B1/en active Active
- 2006-09-11 CA CA2616204A patent/CA2616204C/en active Active
- 2006-09-11 KR KR1020087004005A patent/KR101655455B1/en active IP Right Grant
- 2006-09-11 CN CN2006800316099A patent/CN101252932B/en active Active
- 2006-09-11 ES ES06790661T patent/ES2389666T3/en active Active
- 2006-09-11 CN CNA2006800304941A patent/CN101242856A/en active Pending
- 2006-09-11 BR BRPI0615860A patent/BRPI0615860B8/en active IP Right Grant
- 2006-09-11 NZ NZ565591A patent/NZ565591A/en unknown
- 2006-09-11 EA EA200800783A patent/EA014739B1/en unknown
- 2006-09-11 KR KR1020087004004A patent/KR20080047538A/en not_active Application Discontinuation
- 2006-09-11 ES ES06790660.2T patent/ES2620293T3/en active Active
- 2006-09-11 EP EP06790661A patent/EP1931346B1/en active Active
- 2006-09-11 ZA ZA200801162A patent/ZA200801162B/en unknown
- 2006-09-11 JP JP2008529431A patent/JP5269595B2/en active Active
- 2006-09-11 WO PCT/CA2006/001484 patent/WO2007048220A2/en active Application Filing
- 2006-09-11 JP JP2008529430A patent/JP2009507047A/en active Pending
- 2006-09-11 UA UAA200804463A patent/UA94916C2/en unknown
- 2006-09-11 RU RU2008113439/15A patent/RU2008113439A/en not_active Application Discontinuation
- 2006-09-11 DK DK06790661.0T patent/DK1931346T3/en active
- 2006-09-11 US US11/519,189 patent/US8795723B2/en active Active
- 2006-09-11 DK DK06790660.2T patent/DK1940467T3/en active
- 2006-09-11 AU AU2006308449A patent/AU2006308449B8/en active Active
- 2006-09-11 PT PT06790661T patent/PT1931346E/en unknown
- 2006-09-11 US US11/519,194 patent/US7829120B2/en active Active
- 2006-09-11 PL PL06790661T patent/PL1931346T3/en unknown
- 2006-09-11 AU AU2006308448A patent/AU2006308448A1/en not_active Abandoned
- 2006-09-11 WO PCT/CA2006/001483 patent/WO2007048219A2/en active Application Filing
-
2008
- 2008-01-23 IL IL188964A patent/IL188964A0/en unknown
- 2008-01-31 IL IL189139A patent/IL189139A/en active IP Right Grant
- 2008-03-04 EC EC2008008240A patent/ECSP088240A/en unknown
- 2008-03-04 EC EC2008008239A patent/ECSP088239A/en unknown
- 2008-03-31 NO NO20081593A patent/NO20081593L/en not_active Application Discontinuation
- 2008-04-07 NO NO20081731A patent/NO342381B1/en unknown
-
2009
- 2009-02-09 HK HK09101139.1A patent/HK1124237A1/en unknown
-
2010
- 2010-09-28 US US12/892,454 patent/US9439866B2/en active Active
- 2010-09-28 US US12/892,466 patent/US20110015205A1/en not_active Abandoned
- 2010-10-15 US US12/905,577 patent/US8962019B2/en active Active
- 2010-10-15 US US12/905,567 patent/US8414919B2/en active Active
-
2013
- 2013-03-15 JP JP2013053465A patent/JP2013116917A/en active Pending
-
2015
- 2015-02-23 US US14/628,971 patent/US20150306041A1/en not_active Abandoned
-
2016
- 2016-04-07 US US15/093,468 patent/US20160361262A1/en not_active Abandoned
-
2017
- 2017-09-04 AR ARP170102452A patent/AR109571A2/en not_active Application Discontinuation
Patent Citations (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2987445A (en) * | 1958-10-10 | 1961-06-06 | Rohm & Haas | Drug composition |
US3087860A (en) * | 1958-12-19 | 1963-04-30 | Abbott Lab | Method of prolonging release of drug from a precompressed solid carrier |
US3336200A (en) * | 1963-05-28 | 1967-08-15 | Warner Lambert Pharmaceutical | Tablet structure |
US3381009A (en) * | 1965-12-15 | 1968-04-30 | Acraf | Triazole-(4,3-a)-pyridines |
US3652589A (en) * | 1967-07-27 | 1972-03-28 | Gruenenthal Chemie | 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols |
US4595587A (en) * | 1983-04-18 | 1986-06-17 | Boehringer Ingelheim Kg | Divisible pharmaceutical tablet with delayed active ingredient release |
US4683131A (en) * | 1983-04-18 | 1987-07-28 | Boehringer Ingelheim Kg | Divisible pharmaceutical tablet with delayed active ingredient release |
US4824677A (en) * | 1986-12-18 | 1989-04-25 | The Unjohn Company | Grooved tablet for fractional dosing of sustained release medication |
US5132116A (en) * | 1987-07-16 | 1992-07-21 | Pierre Fabre Medicament | Tablets of the hydrophilic matrix type based on salbutamol and a process for their preparation |
US5004613A (en) * | 1987-07-27 | 1991-04-02 | Mcneil-Ppc, Inc. | Oral sustained release pharmaceutical formulation and process |
US4820522A (en) * | 1987-07-27 | 1989-04-11 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
US4906632A (en) * | 1987-12-02 | 1990-03-06 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F.S | Method of preventing myocardial infarction and acute cerebral ischaemia |
US4938968A (en) * | 1988-07-26 | 1990-07-03 | Norjec Development Associates, Inc. | Controlled release indomethacin |
US5126145A (en) * | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5603956A (en) * | 1990-11-27 | 1997-02-18 | Labopharm Inc. | Cross-linked enzymatically controlled drug release |
US5336691A (en) * | 1991-09-06 | 1994-08-09 | Mcneilab, Inc. | Composition comprising a tramadol material and acetaminophen and its use |
US5407686A (en) * | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
US20030054032A1 (en) * | 1991-12-24 | 2003-03-20 | Benjamin Oshlack | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US6572885B2 (en) * | 1991-12-24 | 2003-06-03 | Euro-Celtique, S.A. | Orally administrable opioid formulations having extended duration of effect |
US5286493A (en) * | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
US5639476A (en) * | 1992-01-27 | 1997-06-17 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5427799A (en) * | 1992-03-25 | 1995-06-27 | Valentine Enterprises, Inc. | Sustained release composition and method utilizing xanthan gum and an active ingredient |
US5520931A (en) * | 1992-07-29 | 1996-05-28 | Gacell Laboratories Ab | Controlled release morphine preparation |
US5414129A (en) * | 1992-09-08 | 1995-05-09 | Chemagis, Ltd. | Process for the purification of 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol and its salts |
US5595762A (en) * | 1992-11-30 | 1997-01-21 | Laboratoires Virbac | Stabilized pulverulent active agents, compositions containing them, process for obtaining them and their applications |
US5616343A (en) * | 1993-03-25 | 1997-04-01 | Labopharm, Inc. | Cross-linked amylose as a binder/disintegrant in tablets |
US7074430B2 (en) * | 1993-05-10 | 2006-07-11 | Euro-Celtique S.A. | Controlled release tramadol tramadol formulation |
US6254887B1 (en) * | 1993-05-10 | 2001-07-03 | Euro-Celtique S.A. | Controlled release tramadol |
US5591452A (en) * | 1993-05-10 | 1997-01-07 | Euro-Celtique, S.A. | Controlled release formulation |
US6103261A (en) * | 1993-07-01 | 2000-08-15 | Purdue Pharma Lp | Opioid formulations having extended controlled release |
US5879705A (en) * | 1993-07-27 | 1999-03-09 | Euro-Celtique S.A. | Sustained release compositions of morphine and a method of preparing pharmaceutical compositions |
US5601842A (en) * | 1993-09-03 | 1997-02-11 | Gruenenthal Gmbh | Sustained release drug formulation containing a tramadol salt |
US6245356B1 (en) * | 1993-09-09 | 2001-06-12 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems-amorphous drugs |
US20030035837A1 (en) * | 1993-11-23 | 2003-02-20 | Sackler Richard S. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US6387404B2 (en) * | 1993-11-23 | 2002-05-14 | Euro-Celtique S.A. | Immediate release tablet cores of insoluble drugs having sustained-release coating |
US6210714B1 (en) * | 1993-11-23 | 2001-04-03 | Euro-Celtique S.A. | Immediate release tablet cores of acetaminophen having sustained-release coating |
US5891471A (en) * | 1993-11-23 | 1999-04-06 | Euro-Celtique, S.A. | Pharmaceutical multiparticulates |
US5888545A (en) * | 1994-07-01 | 1999-03-30 | Arzneimittelwerk Dresden Gmbh | Carbamazepine medicament with retarded active substance release |
US6586006B2 (en) * | 1994-08-04 | 2003-07-01 | Elan Drug Delivery Limited | Solid delivery systems for controlled release of molecules incorporated therein and methods of making same |
US6335033B2 (en) * | 1994-11-04 | 2002-01-01 | Euro-Celtique, S.A. | Melt-extrusion multiparticulates |
US6743442B2 (en) * | 1994-11-04 | 2004-06-01 | Euro-Celtique, S.A. | Melt-extruded orally administrable opioid formulations |
US6261599B1 (en) * | 1994-11-04 | 2001-07-17 | Euro-Celtique, S.A. | Melt-extruded orally administrable opioid formulations |
US6214331B1 (en) * | 1995-06-06 | 2001-04-10 | C. R. Bard, Inc. | Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained |
US5776492A (en) * | 1995-08-19 | 1998-07-07 | Gruenenthal Gmbh | Rapidly disintegrating medicinal form of tramadol or a tramadol salt |
US6399096B1 (en) * | 1995-09-22 | 2002-06-04 | Euro-Celtique S.A. | Pharmaceutical formulation |
US5780057A (en) * | 1996-02-19 | 1998-07-14 | Jagotec Ag | Pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids |
US5773031A (en) * | 1996-02-27 | 1998-06-30 | L. Perrigo Company | Acetaminophen sustained-release formulation |
US5885615A (en) * | 1996-04-10 | 1999-03-23 | Labopharm Inc. | Pharmaceutical controlled release tablets containing a carrier made of cross-linked amylose and hydroxypropylmethylcellulose |
US5874620A (en) * | 1996-08-22 | 1999-02-23 | Chemagis, Ltd. | Process for the purification of (RR-SS)-2-dimethylaminomethyl-1-(3-methoxyphenyl)cyclohexanol hydrochloride |
US6190591B1 (en) * | 1996-10-28 | 2001-02-20 | General Mills, Inc. | Embedding and encapsulation of controlled release particles |
US5879707A (en) * | 1996-10-30 | 1999-03-09 | Universite De Montreal | Substituted amylose as a matrix for sustained drug release |
US6254881B1 (en) * | 1996-12-18 | 2001-07-03 | Bimeda Research & Development Limited | Antiinfective free intramammary veterinary composition |
US6372255B1 (en) * | 1997-12-23 | 2002-04-16 | Merck Patent Gesellschaft | Tablet for instant and prolonged release of one or more active substances |
US5877351A (en) * | 1997-12-24 | 1999-03-02 | Wyckoff Chemical Company, Inc. | Preparation and purification process for 2- (dimethylamino) methyl!-1-(3-methoxphenyl)-cyclohexanol and its salts |
US6419957B1 (en) * | 1998-02-24 | 2002-07-16 | Labopharm, Inc. | Cross-linked high amylose starch having functional groups as a matrix for the slow release of pharmaceutical agents |
US6245357B1 (en) * | 1998-03-06 | 2001-06-12 | Alza Corporation | Extended release dosage form |
US6228875B1 (en) * | 1998-04-14 | 2001-05-08 | The General Hospital Corporation | Methods for treating neuropsychiatric disorders |
US20020052411A1 (en) * | 1998-09-03 | 2002-05-02 | Dagmar Gobel | Valproate compositions and processes for making |
US6245387B1 (en) * | 1998-11-03 | 2001-06-12 | Diamon-Fusion International, Inc. | Capped silicone film and method of manufacture thereof |
US20030104061A1 (en) * | 1999-01-18 | 2003-06-05 | Gruenenthal Gmbh | Controlled release tramadol preparations with a storage-stable release profile and process for their production |
US20020044966A1 (en) * | 1999-01-18 | 2002-04-18 | Johannes Bartholomaeus | Pharmaceutical formulations containing an opioid and an alpha-agonist |
US6685964B1 (en) * | 1999-01-18 | 2004-02-03 | Gruenenthal Gmbh | Opioid analgesics with controlled active substance release |
US6558701B2 (en) * | 1999-06-17 | 2003-05-06 | Gruenenthal Gmbh | Multilayer tablet for administering a fixed combination of tramadol and diclofenac |
US20050003002A1 (en) * | 1999-08-31 | 2005-01-06 | Gruenenthal, Gmbh | Sustained-release, oral pharmaceutical formulations and methods of making and using same |
US6576260B2 (en) * | 1999-08-31 | 2003-06-10 | Gruenenthal Gmbh | Sustained-release form of administration containing tramadol saccharinate |
US20030035835A1 (en) * | 1999-08-31 | 2003-02-20 | Johannes Bartholomaeus | Sustained-release form of administration containing tramadol saccharinate |
US6723343B2 (en) * | 1999-08-31 | 2004-04-20 | Gruenenthal Gmbh | Pharmaceutical tramadol salts |
US20030044464A1 (en) * | 1999-08-31 | 2003-03-06 | Iris Ziegler | Sustained-release, oral pharamaceutical forms of formulation |
US20030069314A1 (en) * | 1999-10-05 | 2003-04-10 | Gruenenthal Gmbh | Use of (+)-tramadol, O-demethyltramadol or (+)-O-demethyl-tramadol, O-desmethyl-N-mono-desmethyl-tramadol or (+)- O-desmethyl-N-mono-desmethyltramadol for the treatment of urinary incontinence |
US20020055544A1 (en) * | 1999-10-12 | 2002-05-09 | Marc Kamin | Analgesic regimen |
US6339105B1 (en) * | 1999-10-12 | 2002-01-15 | Ortho-Mcneil Pharmaceutical, Inc. | Analgesic regimen |
US6569463B2 (en) * | 1999-11-23 | 2003-05-27 | Lipocine, Inc. | Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6211229B1 (en) * | 2000-02-17 | 2001-04-03 | Neil B. Kavey | Treatment of transient and short term insomnia |
US6593373B2 (en) * | 2000-02-21 | 2003-07-15 | Gruenenthal Gmbh | Pharmaceutical compositions of O-desmethyl-N-mono-desmethyl-tramadol |
US20020032239A1 (en) * | 2000-02-21 | 2002-03-14 | Gruenenthal Gmbh | Use of O-desmethyl-N-mono-desmethyl-tramadol |
US20030021846A1 (en) * | 2000-03-27 | 2003-01-30 | Karl Kolter | Active ingredient-containing floating forms comprising polyvinyl acetate and polyvinylpyrrolidone, their use and production |
US20020008133A1 (en) * | 2000-06-14 | 2002-01-24 | Katsuhiro Imasaki | Two-layer clad pipe and method for making the same |
US20020012701A1 (en) * | 2000-06-19 | 2002-01-31 | Karl Kolter | Process for producing solid oral dosage forms with sustained release of active ingredient |
US6733783B2 (en) * | 2000-10-30 | 2004-05-11 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
US20030143270A1 (en) * | 2001-04-11 | 2003-07-31 | Galephar Pharmaceutical Research, Inc. | Extended release composition containing Tramadol |
US20030068371A1 (en) * | 2001-08-06 | 2003-04-10 | Benjamin Oshlack | Pharmaceutical formulation containing opioid agonist,opioid antagonist and gelling agent |
US20030068375A1 (en) * | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
US20030092724A1 (en) * | 2001-09-18 | 2003-05-15 | Huaihung Kao | Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic |
US6863901B2 (en) * | 2001-11-30 | 2005-03-08 | Collegium Pharmaceutical, Inc. | Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration |
US20060009465A1 (en) * | 2002-01-18 | 2006-01-12 | Dale Edgar | Treatment of sleep disorders using sleep target modulators |
US20040131671A1 (en) * | 2002-09-21 | 2004-07-08 | Shuyi Zhang | Sustained release formulations containing acetaminophen and tramadol |
US20060115530A1 (en) * | 2002-10-16 | 2006-06-01 | Anders Pettersson | Gastric acid secretion inhibiting composition |
US20070003618A1 (en) * | 2002-10-25 | 2007-01-04 | Vincent Lenaerts | Sustained-release tramadol formulations with 24-hour efficacy |
US20090047345A9 (en) * | 2002-10-25 | 2009-02-19 | Vincent Lenaerts | Sustained-release tramadol formulations with 24-hour efficacy |
US20040136924A1 (en) * | 2002-12-30 | 2004-07-15 | Boyd Thomas J. | Oral care compositions and methods |
EP1576986A2 (en) * | 2003-10-10 | 2005-09-21 | Labopharm Inc. | Sustained-release tramadol formulations with 24-hour clinical efficacy |
US20050157382A1 (en) * | 2004-01-07 | 2005-07-21 | Kafka James D. | Industrial directly diode-pumped ultrafast amplifier system |
US20060111307A1 (en) * | 2004-11-16 | 2006-05-25 | Wendye Robbins | Methods and compositions for treating pain |
US20070048376A1 (en) * | 2005-08-24 | 2007-03-01 | Penwest Pharmaceuticals Co. | Sustained release formulations of nalbuphine |
US20070128269A1 (en) * | 2005-09-09 | 2007-06-07 | Sonia Gervais | Sustained drug release compositions |
US20110021535A1 (en) * | 2005-09-09 | 2011-01-27 | Sonia Gervais | Trazodone Composition for Once a Day Administration |
US20110027370A1 (en) * | 2005-09-09 | 2011-02-03 | Sonia Gervais | Sustained Drug Release Composition |
US20110033537A1 (en) * | 2005-09-09 | 2011-02-10 | Sonia Gervais | Sustained Drug Release Composition |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070128269A1 (en) * | 2005-09-09 | 2007-06-07 | Sonia Gervais | Sustained drug release compositions |
US20110021535A1 (en) * | 2005-09-09 | 2011-01-27 | Sonia Gervais | Trazodone Composition for Once a Day Administration |
US20110027370A1 (en) * | 2005-09-09 | 2011-02-03 | Sonia Gervais | Sustained Drug Release Composition |
US20110033537A1 (en) * | 2005-09-09 | 2011-02-10 | Sonia Gervais | Sustained Drug Release Composition |
US8414919B2 (en) | 2005-09-09 | 2013-04-09 | Angelini Labopharm, Llc | Sustained drug release composition |
US8795723B2 (en) | 2005-09-09 | 2014-08-05 | Angelini Pharma Inc. | Sustained drug release compositions |
US8962019B2 (en) | 2005-09-09 | 2015-02-24 | Angelini Pharma, Inc. | Sustained drug release composition |
US9439866B2 (en) | 2005-09-09 | 2016-09-13 | Angelini Pharma, Inc. | Trazodone composition for once a day administration |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9439866B2 (en) | Trazodone composition for once a day administration | |
US10441585B2 (en) | Formulations containing nalbuphine and uses thereof | |
US20090130183A1 (en) | Bilayer Composition for the Sustained Release of Acetaminophen and Tramadol | |
EP2295041A2 (en) | HRT formulations | |
WO2020175897A1 (en) | Controlled release formulation containing mirabegron or pharmaceutically acceptable salt thereof | |
EP1781292B1 (en) | Extended release formulation of 3-amino-8-(1-piperazinyl)-2h-1benzopyran-2-one | |
CA2493593A1 (en) | Bicifadine formulation | |
JP2015003901A (en) | Tablet containing irbesartan | |
JP6990470B2 (en) | Lenalidomide gastric retention type sustained release tablet and its preparation method | |
KR102486126B1 (en) | Pharmaceutical compositions comprising alpelisib | |
US20060013874A1 (en) | Extended release formulation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one | |
BRPI0615577B1 (en) | PROLONGED-RELEASE PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
TW202227070A (en) | Solid dispersion formulations of an fxr agonist | |
EP4281048A1 (en) | Prolonged-release furazidin composition | |
CN116887822A (en) | Method for treating achondroplasia | |
WO2010070023A2 (en) | Formulations | |
TW200812585A (en) | Trazodone composition for once a day administration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: LABOPHARM (BARBADOS) LIMITED, BARBADOS Free format text: CHANGE OF ASSIGNEE ADDRESS;ASSIGNOR:LABOPHARM (BARBADOS) LIMITED;REEL/FRAME:025460/0750 Effective date: 20100202 Owner name: LABOPHARM INC., QUEBEC Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GERVAIS, SONIA;SMITH, DAMON;RAHMOUNI, MILOUD;AND OTHERS;SIGNING DATES FROM 20070227 TO 20070424;REEL/FRAME:025470/0639 Owner name: LABOPHARM (BARBADOS) LIMITED - PARTIAL INTEREST (E Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LABOPHARM INC.;REEL/FRAME:025470/0688 Effective date: 20080208 Owner name: LABOPHARM EUROPE LIMITED - PARTIAL INTEREST (ENTIR Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LABOPHARM INC.;REEL/FRAME:025470/0688 Effective date: 20080208 |
|
AS | Assignment |
Owner name: ANGELINI LABOPHARM, LLC, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LABOPHARM INC.;LABOPHARM EUROPE LIMITED;LABOPHARM (BARBADOS) LIMITED;REEL/FRAME:027589/0342 Effective date: 20120120 |
|
AS | Assignment |
Owner name: ANGELINI PHARMA INC., MARYLAND Free format text: MERGER;ASSIGNOR:ANGELINI LABOPHARM, LLC;REEL/FRAME:031107/0661 Effective date: 20121205 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |